var title_f10_48_11008="2D TTE RV inflow";
var content_f10_48_11008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) right ventricular (RV) inflow view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parasternal&nbsp;right ventricular (RV)&nbsp;inflow view&nbsp;from the two-dimensional echocardiogram shows the RV and atrium (RA) and the septal and&nbsp;anterior leaflets of the tricuspid valve (TV). The entrance of the coronary sinus into the RA is separated from the entrance of the inferior vena cava by the eustachian valve (EV).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_48_11008=[""].join("\n");
var outline_f10_48_11008=null;
var title_f10_48_11009="Nonorganic ptosis right lid";
var content_f10_48_11009=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F64679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F64679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Nonorganic ptosis of the right upper lid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrary to expected, the patient is raising the left eyebrow and depressing the right eyebrow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Lee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_48_11009=[""].join("\n");
var outline_f10_48_11009=null;
var title_f10_48_11010="Bullous impetigo infant";
var content_f10_48_11010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bullous impetigo in an infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_48_11010=[""].join("\n");
var outline_f10_48_11010=null;
var title_f10_48_11011="Patient information: High cholesterol (The Basics)";
var content_f10_48_11011=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15330\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?28/50/29483\">",
"         Cholesterol and triglyceride measurements in the United States and elsewhere",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?23/5/23635\">",
"         Patient information: Atherosclerosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/56/24450\">",
"         Patient information: Can foods or supplements lower cholesterol? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/30/483\">",
"         Patient information: Dealing with side effects from medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/30/5602\">",
"         Patient information: Familial hypercholesterolemia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/28/20930\">",
"         Patient information: High triglycerides (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/43/37554\">",
"         Patient information: Medicine brand and generic names (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/4/6212\">",
"         Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/6/43108\">",
"         Patient information: High cholesterol treatment options (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/61/32726\">",
"         Patient information: Reducing the costs of medicines (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: High cholesterol (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/high-cholesterol-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H25074010\">",
"      <span class=\"h1\">",
"       What is cholesterol?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cholesterol is a substance that is found in the blood. Everyone has some. It is needed for good health. The problem is, people sometimes have too much cholesterol. Compared with people with normal cholesterol, people with high cholesterol have a higher risk of heart attacks, strokes, and other health problems. The higher your cholesterol, the higher your risk of these problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25074017\">",
"      <span class=\"h1\">",
"       Are there different types of cholesterol?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, there are a few different types. If you get a cholesterol test, you may hear your doctor or nurse talk about:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Total cholesterol",
"       </li>",
"       <li>",
"        LDL cholesterol &ndash; Some people call this the &ldquo;bad&rdquo; cholesterol. That&rsquo;s because having high LDL levels",
"        <strong>",
"         raises",
"        </strong>",
"        your risk of heart attacks, strokes, and other health problems.",
"       </li>",
"       <li>",
"        HDL cholesterol &ndash; Some people call this the &ldquo;good&rdquo; cholesterol. That&rsquo;s because having high HDL levels",
"        <strong>",
"         lowers",
"        </strong>",
"        your risk of heart attacks, strokes, and other health problems.",
"       </li>",
"       <li>",
"        Non-HDL cholesterol",
"        <strong>",
"         -",
"        </strong>",
"        Non-HDL cholesterol is your total cholesterol minus your HDL cholesterol.",
"       </li>",
"       <li>",
"        Triglycerides &ndash; Triglycerides are not cholesterol. They are a type of fat. But they often get measured when cholesterol is measured. (Having high triglycerides also seems to increase the risk of heart attacks and strokes.)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25074024\">",
"      <span class=\"h1\">",
"       What should my numbers be?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ask your doctor or nurse what your numbers should be. Different people need different goals. (If you live outside the United States, see (",
"      <a class=\"graphic graphic_table graphicRef76734 \" href=\"UTD.htm?28/50/29483\">",
"       table 1",
"      </a>",
"      )). In general, people who do not already have heart disease should aim for:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Total cholesterol below 200",
"       </li>",
"       <li>",
"        LDL cholesterol below 130 &ndash; or much lower, if they are at risk of heart attacks or strokes",
"       </li>",
"       <li>",
"        HDL cholesterol above 60",
"       </li>",
"       <li>",
"        Non-HDL cholesterol below 160 &ndash; or lower, if they are at risk of heart attacks or strokes",
"       </li>",
"       <li>",
"        Triglycerides below 150",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Keep in mind, though, that many people who cannot meet these goals still have a low risk of heart attacks and strokes.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25074031\">",
"      <span class=\"h1\">",
"       What should I do if my doctor tells me I have high cholesterol?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Ask your doctor what your",
"      <strong>",
"       overall",
"      </strong>",
"      risk of heart attacks and strokes is. High cholesterol, by itself, is not always a reason to worry. Having high cholesterol is just one of many things that can increase your risk of heart attacks and strokes. Other factors that increase your risk include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Cigarette smoking",
"       </li>",
"       <li>",
"        High blood pressure",
"       </li>",
"       <li>",
"        Having a parent, sister, or brother who got heart disease at a young age (Young, in this case, means younger than 55 for men and younger than 65 for women.)",
"       </li>",
"       <li>",
"        Being a man (Women are at risk, too, but men have a higher risk.)",
"       </li>",
"       <li>",
"        Older age",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you are at high risk of heart attacks and strokes, having high cholesterol is a problem. On the other hand, if you have are at low risk, having high cholesterol may not mean much.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25074038\">",
"      <span class=\"h1\">",
"       Should I take medicine to lower cholesterol?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not everyone who has high cholesterol needs medicines. Your doctor or nurse will decide if you need them based on your age, family history, and other health concerns.",
"     </p>",
"     <p>",
"      You should probably take a cholesterol-lowering medicine called a statin if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Already had a heart attack or stroke",
"       </li>",
"       <li>",
"        Have known heart disease",
"       </li>",
"       <li>",
"        Have diabetes",
"       </li>",
"       <li>",
"        Have a condition called peripheral artery disease, which makes it painful to walk, and happens when the arteries in your legs get clogged with fatty deposits",
"       </li>",
"       <li>",
"        Have an abdominal aortic aneurysm, which is a widening of the main artery in the belly",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most people with any of the conditions listed above should take a statin no matter what their cholesterol level is. If your doctor or nurse puts you on a statin, stay on it. The medicine may not make you feel any different. But it can help prevent heart attacks, strokes, and death.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25074045\">",
"      <span class=\"h1\">",
"       Can I lower my cholesterol without medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, you can lower your cholesterol some by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Avoiding red meat, butter, fried foods, cheese, and other foods that have a lot of saturated fat",
"       </li>",
"       <li>",
"        Losing weight (if you are overweight)",
"       </li>",
"       <li>",
"        Being more active",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Even if these steps do little to change your cholesterol, they can improve your health in many ways.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25074136\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/30/5602?source=see_link\">",
"       Patient information: Familial hypercholesterolemia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/5/23635?source=see_link\">",
"       Patient information: Atherosclerosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/43/37554?source=see_link\">",
"       Patient information: Medicine brand and generic names (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=see_link\">",
"       Patient information: Dealing with side effects from medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/28/20930?source=see_link\">",
"       Patient information: High triglycerides (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/56/24450?source=see_link\">",
"       Patient information: Can foods or supplements lower cholesterol? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"       Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=see_link\">",
"       Patient information: High cholesterol treatment options (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       Patient information: Reducing the costs of medicines (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/48/11011?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15330 Version 8.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-D70169F40B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_48_11011=[""].join("\n");
var outline_f10_48_11011=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25074010\">",
"      What is cholesterol?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25074017\">",
"      Are there different types of cholesterol?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25074024\">",
"      What should my numbers be?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25074031\">",
"      What should I do if my doctor tells me I have high cholesterol?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25074038\">",
"      Should I take medicine to lower cholesterol?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25074045\">",
"      Can I lower my cholesterol without medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25074136\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15330\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/50/29483\">",
"      Cholesterol and triglyceride measurements in the United States and elsewhere",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/5/23635?source=related_link\">",
"      Patient information: Atherosclerosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/56/24450?source=related_link\">",
"      Patient information: Can foods or supplements lower cholesterol? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/30/5602?source=related_link\">",
"      Patient information: Familial hypercholesterolemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=related_link\">",
"      Patient information: High cholesterol treatment options (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/28/20930?source=related_link\">",
"      Patient information: High triglycerides (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/43/37554?source=related_link\">",
"      Patient information: Medicine brand and generic names (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_48_11012="Projected height B";
var content_f10_48_11012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Estimating projected height using skeletal age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 703px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Projected height for a child older than two years can be determined by extrapolating the child's growth along the current channel to the 18- to 20-year mark. For children with delayed or accelerated growth, using the skeletal age (bone age) rather than the chronologic age to determine the projected height channel provides more accurate assessment of projected height. In the example above, the 10-year-old boy has a skeletal age of 8 years; he is 49 inches tall (&lt;3",
"    <sup>",
"     rd",
"    </sup>",
"    percentile for chronologic age [point A], but 25",
"    <sup>",
"     th",
"    </sup>",
"    percentile for skeletal age [point B]). His projected height is the 25",
"    <sup>",
"     th",
"    </sup>",
"    percentile height for a 20-year-old (point C): 68 inches.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_48_11012=[""].join("\n");
var outline_f10_48_11012=null;
var title_f10_48_11013="Trochanteric osteomyelitis";
var content_f10_48_11013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Osteomyelitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    STIR coronal image of the pelvis shows bone marrow edema of the left femoral greater trochanter (arrow) and intertrochanteric region with extensive surrounding muscle edema consistent with osteomyelitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_48_11013=[""].join("\n");
var outline_f10_48_11013=null;
var title_f10_48_11014="Emergency airway management in the geriatric patient";
var content_f10_48_11014=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emergency airway management in the geriatric patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/48/11014/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11014/contributors\">",
"     Calvin A Brown, III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11014/contributors\">",
"     Christian Arbelaez, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/48/11014/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11014/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/48/11014/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11014/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/48/11014/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;US Census data estimate that 77 million Americans, or nearly 20 percent of the overall population, will be over age 65 by the year 2030 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11014/abstract/1\">",
"     1",
"    </a>",
"    ]. Similar trends are apparent throughout the developed world. The increase in the number of older adults has been accompanied by an increase in the use of health care, including the emergency department (ED), by patients with significant comorbid conditions such as diabetes, coronary artery disease (CAD), chronic obstructive pulmonary disease (COPD), and cancer.",
"   </p>",
"   <p>",
"    Many older patients with comorbid disease will require airway management during the course of their illness. Increased patient age and its associated comorbidities affect airway management in three principal areas:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased likelihood of requiring intubation during acute illness",
"     </li>",
"     <li>",
"      Increased difficulty performing bag-mask ventilation and intubation",
"     </li>",
"     <li>",
"      Adjustments in drug selection and dosing for rapid sequence intubation (RSI)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Airway management in geriatric patients will be reviewed here. Topic reviews covering general airway management and the performance of RSI are found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=see_link\">",
"     \"Advanced emergency airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31288?source=see_link\">",
"     \"Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38775?source=see_link\">",
"     \"Pretreatment agents for rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=see_link\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=see_link\">",
"     \"The decision to intubate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFECTS OF AGING AND NEED FOR INTUBATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Physiologic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging brings a number of physiologic changes that affect respiratory and cardiovascular function and that complicate airway management. Among the most important are [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11014/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lung parenchymal changes resulting in impaired gas exchange and reduced PaO2",
"     </li>",
"     <li>",
"      Decreased lung elasticity and increased ventilation-perfusion mismatch",
"     </li>",
"     <li>",
"      Decreased chest wall compliance and respiratory muscle strength, leading to increased work of breathing and higher risk of respiratory failure",
"     </li>",
"     <li>",
"      Reduced cough and mucociliary clearance, and possibly neuromuscular deconditioning, increasing the risk from aspiration",
"     </li>",
"     <li>",
"      Reduced responsiveness of brain respiratory centers to hypoxemia and hypercarbia",
"     </li>",
"     <li>",
"      Diminished overall cardiopulmonary reserve, resulting in heightened sensitivity to the negative inotropy and vasodilatory effects of induction agents and other vasoactive drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chronic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to distinguish between changes due to the physiology of aging and pathologic changes brought on by chronic disease. Despite the contributory role played by the physiologic factors described above, data suggest that comorbid conditions, and",
"    <strong>",
"     not",
"    </strong>",
"    age, play the most important role in determining patient outcome after respiratory failure in elders [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11014/abstract/2\">",
"     2",
"    </a>",
"    ]. As an example, a vigorous octogenarian who exercises daily has far more physiologic reserve and will tolerate the stress of acute illness far better than her bed-bound counterpart with cerebrovascular or cardiovascular disease.",
"   </p>",
"   <p>",
"    Nevertheless, chronic illness and disability are more common in elders. Exacerbations of chronic pulmonary and cardiac diseases often exhaust the patient's limited cardiopulmonary reserve, leading to respiratory distress or failure and the need for intubation. Such patients may not tolerate the greater work of breathing, leading to respiratory failure much earlier than in their healthier or younger counterparts. In addition, acquired illnesses, such as community or hospital acquired pneumonia or urinary tract infection, can progress to sepsis and rapidly deplete physiologic reserves in susceptible geriatric patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and causes of heart failure\", section on 'Incidence in older adults'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/52/15178?source=see_link\">",
"     \"Immune function in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ethical considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians providing emergency or critical care to elders must consider patient wishes. Where practical, clinicians should enquire regarding the presence of advanced directives (code status) and attempt to determine patient desires regarding invasive measures such as intubation by review of existing documentation or discussion with the patient, the patient's family, or the primary care physician.",
"   </p>",
"   <p>",
"    \"Do not intubate\" and \"do not resuscitate\" status must not be assumed, and patient age alone is never an indication to withhold care in the context of an acute illness. Studies suggest that clinicians caring for elders at the end of life often underestimate the level of resuscitation desired by the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11014/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the clinician managing the patient with acute deterioration is not able to determine the patient's wishes or code status, it generally is best to proceed with resuscitation and intubation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=see_link\">",
"     \"Ethical issues near the end of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     AIRWAY DIFFICULTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both bag-mask ventilation and intubation are more likely to be difficult in elders. The general approach to the difficult airway in adults is discussed separately; issues of particular relevance to geriatric patients are discussed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elderly, edentulous patients are harder to ventilate with a bag-valve mask. The loss of upper airway muscle tone and loose lips unsupported by teeth make mask seal and maintenance of a patent airway more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11014/abstract/4\">",
"     4",
"    </a>",
"    ]. A stiffer chest wall also increases the difficulty of ventilation with a bag-valve mask or a rescue airway (eg, laryngeal mask airway).",
"   </p>",
"   <p>",
"    Baseline oxygen saturation is often low in the elderly, and adequate preoxygenation may be difficult or impossible. In addition, elders desaturate more rapidly than healthy, younger patients. In the following figure, the curve for chronically ill patients can be used to approximate desaturation for elders (",
"    <a class=\"graphic graphic_figure graphicRef56716 \" href=\"UTD.htm?2/58/2976\">",
"     figure 1",
"    </a>",
"    ). Thus, the safe apnea period is decreased despite best attempts at preoxygenation compared with routine intubations in younger, healthy adults.",
"   </p>",
"   <p>",
"    The elderly are more susceptible to hypoxic insults. Even brief periods of oxygen desaturation can result in permanent cardiac and neurologic damage. Whenever possible, the airway manager should maintain the oxyhemoglobin saturation at or above 90 percent, even if this requires aborting an attempt at laryngoscopy in order to oxygenate by bag and mask or with an extraglottic device.",
"   </p>",
"   <p>",
"    When difficult airway assessment indicates that the patient is unlikely to be successfully intubated by direct laryngoscopy, an awake approach to intubation is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link&amp;anchor=H21#H21\">",
"     \"The difficult airway in adults\", section on 'Awake technique'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Video laryngoscopes improve the rate of successful laryngoscopy and so may permit rapid sequence intubation in patients for whom direct laryngoscopy with a conventional laryngoscope is not likely to provide an adequate glottic view. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/55/25466?source=see_link&amp;anchor=H12#H12\">",
"     \"Devices for difficult emergency airway management in adults\", section on 'Video laryngoscopes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DRUG SELECTION FOR RAPID SEQUENCE INTUBATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Overview of medications and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the higher incidence of difficult airways in elders, most are appropriate candidates for rapid sequence intubation (RSI). When performing RSI, drug selection and drug dosing are of great importance. The medications used for RSI cause more pronounced hypopnea and hypotension in the elderly than in younger, healthy patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11014/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Therefore, it is generally best to reduce the doses of short-acting opioids used for pretreatment and induction agents by approximately 30 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11014/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Standard dosing is used for neuromuscular blocking agents.",
"   </p>",
"   <p>",
"    The general performance of RSI and the medications used in the procedure are discussed separately. Issues of particular importance to RSI in older patients are reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31288?source=see_link\">",
"     \"Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38775?source=see_link\">",
"     \"Pretreatment agents for rapid sequence intubation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=see_link\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pretreatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for pretreatment of elder patients are extrapolated from evidence related to younger or mixed patient populations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38775?source=see_link\">",
"     \"Pretreatment agents for rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Short-acting opioids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    ) may be given to elders at risk from the hypertension caused by the sympathetic response stimulated by laryngoscopy and intubation. However, careful assessment of the risks and benefits is important because of the increased sensitivity of elders to the hypoventilatory effects of opioids.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    may be given to elders with increased intracranial pressure or increased airway resistance in need of intubation.",
"   </p>",
"   <p>",
"    Examples of patients who may benefit from opioids include those with cardiovascular disease or cerebral vascular disease with hypertension or intracranial hemorrhage. We suggest reducing the dose of short-acting opioids used for pretreatment by 50 percent, to a dose of 1 to 1.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    because elder patients are more susceptible to adverse effects from both hypotension and respiratory depression.",
"   </p>",
"   <p>",
"    In a randomized double-blind study of 40 elderly (age &gt;65), higher-risk (ASA Class III) surgical patients, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    (loading dose 0.5",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/9/3223?source=see_link\">",
"     alfentanil",
"    </a>",
"    (loading dose 10",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    attenuated the sympathetic response to laryngoscopy when administered prior to the induction of general anesthesia, but both were associated with significant hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11014/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    has not been studied as a pretreatment agent in older patients but is relatively safe and may be of benefit in select patients. It is given in the standard dose of 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    approximately three minutes before administration of the induction and neuromuscular blocking agents.",
"   </p>",
"   <p>",
"    Pretreatment doses of non-depolarizing neuromuscular blockers (typically one-tenth the full paralytic dose) are of no proven benefit, and can sometimes cause complete paralysis (and apnea) in the elderly, and so are not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     Etomidate",
"    </a>",
"    is the preferred induction agent for elderly patients undergoing RSI. Etomidate is a sedative-hypnotic medication that maintains hemodynamic stability and has a rapid and reliable onset of action and a short duration of effect [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11014/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. Hemodynamic stability is of particular importance in geriatric patients, who are at risk of large fluctuations in blood pressure from potent sedatives. The pharmacology and use of etomidate is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=see_link&amp;anchor=H5#H5\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\", section on 'Etomidate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, in a hemodynamically compromised patient,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    can exacerbate hypotension, a matter of particular concern in elders with underlying cerebrovascular or cardiovascular disease. In elders with tenuous cardiovascular reserve or hypotension (systolic blood pressure &lt;100 mmHg), we recommend reducing the induction dose of etomidate by 50 percent to 0.15",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     Midazolam",
"    </a>",
"    is a short-acting benzodiazepine sometimes used for induction during RSI. Midazolam is more likely to cause hypotension than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    and should be used in reduced doses (0.1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    in any patient 65 years of age or older and in those with hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11014/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=see_link&amp;anchor=H8#H8\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\", section on 'Benzodiazepines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neuromuscular blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of two small trials, one randomized and the other observational, suggest that the dose of neuromuscular blocking agent (NMBA) needed to achieve full paralysis is lower and the duration of effect longer in geriatric patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11014/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Nevertheless, we believe the risks associated with poor intubating conditions and failed intubation attempts from incomplete paralysis outweigh any potential risk of prolonged paralysis. Therefore, pending further studies, we suggest using standard dosing for NMBAs when intubating elderly patients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     Succinylcholine",
"    </a>",
"    , in its usual dose of 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of actual body weight, is the drug of choice for RSI in elders, unless contraindications are present. Contraindications to succinylcholine are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31288?source=see_link&amp;anchor=H6#H6\">",
"     \"Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults\", section on 'Contraindications and side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elder patients are much more likely than their younger counterparts to have experienced denervating stroke. Denervation occurring between three days and six months prior to RSI predisposes the patient to severe and rapid-onset hyperkalemia if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    is used. Therefore, if clinical evidence of a prior denervating stroke is present, and it cannot be ascertained with certainty that the stroke occurred more than six months earlier, we recommend use of a competitive NMBA, preferably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    for paralysis during RSI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The physiologic changes and increased rates of chronic illness associated with aging increase the likelihood that emergency airway management will be necessary during acute illness. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Effects of aging and need for intubation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bag-mask ventilation and endotracheal intubation are more likely to be difficult in the geriatric patient. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Airway difficulty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most elderly patients are appropriate candidates for rapid sequence intubation (RSI). Some of the medications used for RSI cause more pronounced hypopnea and hypotension in the elderly, particularly those with comorbid illness. Therefore, in frail, hemodynamically compromised, or comorbidly ill patients, it is generally best to reduce the doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      (used for pretreatment) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      (used for induction) by 50 percent or more. Standard dosing is used for neuromuscular blocking agents. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Overview of medications and dosing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Neuromuscular blockade'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Pretreatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemodynamic stability is of particular importance in geriatric patients, who are at risk of large fluctuations in blood pressure from potent sedatives. Therefore, we suggest that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      be used for induction in elderly patients undergoing RSI (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Induction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Smith D. The Older Population in the United States as of March 2002. US Census Bureau Current Populations Report; US Census Bureau, Washington, DC 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11014/abstract/2\">",
"      Sevransky JE, Haponik EF. Respiratory failure in elderly patients. Clin Geriatr Med 2003; 19:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11014/abstract/3\">",
"      Frank C, Heyland DK, Chen B, et al. Determining resuscitation preferences of elderly inpatients: a review of the literature. CMAJ 2003; 169:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11014/abstract/4\">",
"      Langeron O, Masso E, Huraux C, et al. Prediction of difficult mask ventilation. Anesthesiology 2000; 92:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11014/abstract/5\">",
"      Cressey DM, Claydon P, Bhaskaran NC, Reilly CS. Effect of midazolam pretreatment on induction dose requirements of propofol in combination with fentanyl in younger and older adults. Anaesthesia 2001; 56:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11014/abstract/6\">",
"      Jones NA, Elliott S, Knight J. A comparison between midazolam co-induction and propofol predosing for the induction of anaesthesia in the elderly. Anaesthesia 2002; 57:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11014/abstract/7\">",
"      Martin G, Glass PS, Breslin DS, et al. A study of anesthetic drug utilization in different age groups. J Clin Anesth 2003; 15:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11014/abstract/8\">",
"      Vuyk J. Pharmacodynamics in the elderly. Best Pract Res Clin Anaesthesiol 2003; 17:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11014/abstract/9\">",
"      Habib AS, Parker JL, Maguire AM, et al. Effects of remifentanil and alfentanil on the cardiovascular responses to induction of anaesthesia and tracheal intubation in the elderly. Br J Anaesth 2002; 88:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11014/abstract/10\">",
"      Benson M, Junger A, Fuchs C, et al. Use of an anesthesia information management system (AIMS) to evaluate the physiologic effects of hypnotic agents used to induce anesthesia. J Clin Monit Comput 2000; 16:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11014/abstract/11\">",
"      Guldner G, Schultz J, Sexton P, et al. Etomidate for rapid-sequence intubation in young children: hemodynamic effects and adverse events. Acad Emerg Med 2003; 10:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11014/abstract/12\">",
"      Sokolove PE, Price DD, Okada P. The safety of etomidate for emergency rapid sequence intubation of pediatric patients. Pediatr Emerg Care 2000; 16:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11014/abstract/13\">",
"      Gauss A, Heinrich H, Wilder-Smith OH. Echocardiographic assessment of the haemodynamic effects of propofol: a comparison with etomidate and thiopentone. Anaesthesia 1991; 46:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11014/abstract/14\">",
"      Choi YF, Wong TW, Lau CC. Midazolam is more likely to cause hypotension than etomidate in emergency department rapid sequence intubation. Emerg Med J 2004; 21:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11014/abstract/15\">",
"      Motamed C, Donati F. Intubating conditions and blockade after mivacurium, rocuronium and their combination in young and elderly adults. Can J Anaesth 2000; 47:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11014/abstract/16\">",
"      Baykara N, Solak M, Toker K. Predicting recovery from deep neuromuscular block by rocuronium in the elderly. J Clin Anesth 2003; 15:328.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 284 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-5A6B11C91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_48_11014=[""].join("\n");
var outline_f10_48_11014=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFECTS OF AGING AND NEED FOR INTUBATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Physiologic changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chronic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ethical considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      AIRWAY DIFFICULTY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DRUG SELECTION FOR RAPID SEQUENCE INTUBATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Overview of medications and dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pretreatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Induction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neuromuscular blockade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/284\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/284|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/58/2976\" title=\"figure 1\">",
"      Time to oxygen desaturation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=related_link\">",
"      Advanced emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/55/25466?source=related_link\">",
"      Devices for difficult emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=related_link\">",
"      Epidemiology and causes of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44024?source=related_link\">",
"      Ethical issues near the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/52/15178?source=related_link\">",
"      Immune function in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31288?source=related_link\">",
"      Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38775?source=related_link\">",
"      Pretreatment agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=related_link\">",
"      Sedation or induction agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22726?source=related_link\">",
"      The decision to intubate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_48_11015="Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn";
var content_f10_48_11015=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/48/11015/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11015/contributors\">",
"     Olaf A Bodamer, MD, FACMG, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11015/contributors\">",
"     Geoffrey Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/48/11015/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11015/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11015/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/48/11015/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11015/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/48/11015/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns with neuromuscular disorders often present with hypotonia and weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34004?source=see_link\">",
"     \"Approach to the infant with hypotonia and weakness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These disorders are caused by a variety of conditions that affect the central nervous system (brain or spinal cord), peripheral nervous system, or skeletal muscle. Conditions that affect the last two sites are reviewed briefly here (",
"    <a class=\"graphic graphic_table graphicRef66572 \" href=\"UTD.htm?27/44/28365\">",
"     table 1",
"    </a>",
"    ). More complete discussions of these conditions and of disorders caused by upper motor neuron lesions that involve the descending motor tracts within the brain and spinal cord and of other systemic conditions (eg, Prader-Willi syndrome, Angelman syndrome, multiple minor congenital anomaly syndromes, or inborn errors of metabolism) are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=see_link\">",
"     \"Inborn errors of metabolism: Classification\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTERIOR HORN CELL DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many conditions are caused by degeneration of the anterior horn cells of the spinal cord. They include spinal muscular atrophy, traumatic myelopathy, hypoxic-ischemic myelopathy, and neurogenic arthrogryposis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Spinal muscular atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common and severe type that presents in newborns is spinal muscular atrophy (SMA) type 1, also known as Werdnig-Hoffmann disease. This condition should be suspected in infants with diffuse symmetric proximal muscle weakness that is greater in the lower than upper limbs and absent or markedly decreased deep tendon reflexes. SMA types 2 and 3 have later onset and are less severe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=see_link\">",
"     \"Spinal muscular atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Traumatic myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myelopathy caused by trauma to the high cervical spinal cord is a rare cause of hypotonia in infants. This condition results in a flaccid paralysis, which may be asymmetric, and absent reflexes. Physical examination may reveal evidence of trauma, such as bruising or fractures. If no accompanying brain injury is present, the infant will be alert with no cranial nerve abnormalities. A pin prick on the face will elicit a facial grimace but no response below the neck. A useful sign is withdrawal to a noxious stimulus of a limb with no spontaneous activity. Bladder distension, priapism, and absence of sweating below the level of the spinal lesion typically will appear as the myelopathy evolves over several days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hypoxic-ischemic myelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe hypoxic-ischemic injury occasionally can result in hypotonia or flaccid paralysis with diminished or absent reflexes. Affected infants typically have encephalopathy and may have seizures or other signs of end-organ damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Arthrogryposis multiplex congenita",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthrogryposis (joint contractures) multiplex congenita is a heterogeneous group of disorders characterized by contractures of multiple joints and degeneration of motor neurons. Most cases are neurogenic; the remainder result from primary muscle disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=see_link&amp;anchor=H11#H11\">",
"     \"Spinal muscular atrophy\", section on 'Arthrogryposis multiplex congenita'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CONGENITAL NEUROPATHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital motor or sensory neuropathies can cause hypotonia and weakness that present during the neonatal period or early infancy. The most important of these conditions are the congenital motor sensory neuropathies and the hereditary sensory and autonomic neuropathies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Congenital motor sensory neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital (hereditary) motor and sensory neuropathies comprise a heterogeneous group of disorders that affect the peripheral nervous system. These disorders represent a spectrum of diseases caused by mutations in one of several myelin genes that result in defects in myelin structure, maintenance, or formation. Charcot-Marie-Tooth disease is the most common of these conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hereditary sensory and autonomic neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary sensory and autonomic neuropathies are a group of rare disorders that selectively affect peripheral sensory and autonomic neurons (",
"    <a class=\"graphic graphic_table graphicRef59426 \" href=\"UTD.htm?2/8/2187\">",
"     table 2",
"    </a>",
"    ). They present in infancy and result in a variable extent of autonomic dysfunction or insensitivity to pain and temperature. The most common hereditary sensory and autonomic neuropathy is familial dysautonomia (Riley-Day syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=see_link\">",
"     \"Hereditary sensory and autonomic neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     NEUROMUSCULAR JUNCTION DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of the neuromuscular junction are characterized by abnormal neuromuscular transmission, leading to muscle fatigability and weakness. These rare conditions include transient acquired neonatal myasthenia, congenital myasthenia, toxicity caused by magnesium or aminoglycosides, and infant botulism. Although most of these disorders are transient, congenital forms sometimes may be permanent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=see_link\">",
"     \"Neuromuscular junction disorders in newborns and infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CONGENITAL MYOPATHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital myopathies are primary muscle disorders that are present from birth, although their expression may be delayed until later in infancy or childhood. They present with hypotonia and weakness that is greater proximally than distally. The most common diseases are nemaline myopathy, central core disease, myotubular myopathy, congenital fiber type disproportion, and multicore myopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13417?source=see_link\">",
"     \"Congenital myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MUSCULAR DYSTROPHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscular dystrophies are an inherited group of progressive myopathic disorders resulting from defects in numerous genes required for normal muscle function. Some present in the newborn period (",
"    <a class=\"graphic graphic_table graphicRef66572 \" href=\"UTD.htm?27/44/28365\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dystrophinopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Duchenne and Becker muscular dystrophies are caused by mutations of the dystrophin gene and, therefore, are named dystrophinopathies. Although histologic and laboratory evidence of a myopathy may be observed from birth among male children with Duchenne muscular dystrophy, the clinical onset of weakness usually occurs between two and three years of age, or later. The age of onset of symptoms usually is later and the degree of clinical involvement milder in Becker than Duchenne muscular dystrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=see_link\">",
"     \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Congenital muscular dystrophies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital muscular dystrophies include a number of conditions in which infants are hypotonic and weak at birth and in which muscle biopsies show changes consistent with muscular dystrophy. Arthrogryposis (joint contractures) commonly is observed in the newborn period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=see_link&amp;anchor=H16#H16\">",
"     \"Oculopharyngeal, distal, and congenital muscular dystrophies\", section on 'Congenital muscular dystrophies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These disorders are classified according to the association with brain malformations and the presence or absence of merosin (a component of the dystrophin-associated protein complex) deficiency. Types associated with brain malformations include Fukuyama type, Walker-Warburg syndrome, and muscle-eye-brain disease. Walker-Warburg syndrome and muscle-eye-brain may be due to congenital defects in post-translational protein glycosylation, although genetic heterogeneity has been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Facioscapulohumeral muscular dystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Onset of the classical form of this disorder usually is in the second or third decade, and progression typically is slow. However, the infantile form has an earlier onset (usually within the first few years of life) and is rapidly progressive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/34/26153?source=see_link\">",
"     \"Facioscapulohumeral muscular dystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Congenital myotonic dystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic form of myotonic dystrophy has its onset in adolescence or adulthood. The congenital form of the disease occurs in infants born to mothers with myotonic dystrophy. Patients may present with profound hypotonia at birth occurring in association with facial diplegia, feeding, respiratory difficulties, and skeletal deformities such as clubfeet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link&amp;anchor=H18#H18\">",
"     \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\", section on 'Congenital myotonic dystrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     INBORN ERRORS OF METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain inborn errors of metabolism can present with progressive muscular hypotonia and weakness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute muscle dysfunction with muscle breakdown or myoglobinuria. These conditions include disorders of glycogen, lipid, peroxisomal, creatine, and mitochondrial metabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=see_link\">",
"     \"Inborn errors of metabolism: Classification\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Disorders of glycogen metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the disorders of glycogen metabolism, only acid maltase deficiency (Pompe disease) typically affects newborns. This condition results in accumulation of glycogen within the lysosomes of tissues, including anterior horn cells of the spinal cord, skeletal muscles, brain, heart, and liver. Affected infants usually develop hypotonia and weakness in the first few weeks after birth, as well as significant cardiomegaly, moderate hepatomegaly, and macroglossia. Early diagnosis of Pompe disease is essential, as specific enzyme replacement therapy is available and appears to benefit affected infants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17736?source=see_link\">",
"     \"Lysosomal acid maltase deficiency (glycogen storage disease II, Pompe disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other abnormalities of glycogen metabolism, such as phosphorylase b kinase deficiency, phosphoglycerate kinase deficiency, and branching enzyme deficiency, typically present later in childhood but can present with hypotonia in infancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Primary carnitine deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary systemic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    deficiency is a disorder of fatty acid oxidation caused by a deficiency of the organic",
"    <span class=\"nowrap\">",
"     cation/carnitine",
"    </span>",
"    transporter in the plasma membrane, resulting in defective transport of carnitine from plasma into the cells of affected tissues. This condition typically presents in late infancy or early childhood but can present in the newborn period with weakness, hypotonia, and cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link&amp;anchor=H2#H2\">",
"     \"Causes of metabolic myopathies\", section on 'Carnitine deficiency syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Peroxisomal disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peroxisomal disorders can present during the neonatal period with profound hypotonia and weakness. Signs include central nervous system dysfunction, facial dysmorphism (as in Zellweger syndrome), hepatomegaly, cataracts, retinopathy, calcific stippling of epiphyses, and rhizomelia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link\">",
"     \"Peroxisomal disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Disorders of creatine metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of creatine metabolism encompass three distinct inborn errors of metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11015/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Guanidinoacetate methyltransferase (GAMT) deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?10/48/11015/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Arginine-glycine amidinotransferase (AGAT) deficiency",
"     </li>",
"     <li>",
"      Creatine transporter (CRTR) deficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical features include muscular hypotonia, epilepsy, extrapyramidal symptoms, and developmental delay. Creatine supplementation and dietary intervention may benefit patients with GAMT and AGAT deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11015/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Mitochondrial myopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondrial myopathies consist of primary abnormalities of mitochondrial structure and function with an associated involvement of muscle. They are caused by defects of substrate transport, substrate utilization (including the citric acid cycle), and the respiratory chain (oxidative phosphorylation coupling). Respiratory chain abnormalities are most likely to lead to prominent muscle disease in the newborn. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mitochondrial myopathy should be suspected in an infant with weakness and lactic acidosis, especially if multisystem involvement is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Cytochrome c oxidase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytochrome c oxidase (COX, complex IV) deficiency is the most common respiratory chain disorder causing myopathy in newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11015/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The enzyme deficiency results in impairment of energy production. Affected patients present within the first days or weeks with profound generalized weakness, hypotonia, hyporeflexia, poor feeding, respiratory difficulty, and lactic acidosis (caused by decreased utilization of pyruvate, which is then converted to lactate). They also may have macroglossia, hepatomegaly, and cardiomyopathy. The disease is fatal within a few months. Some of these individuals have renal defects (de Toni-Debr&eacute;-Fanconi syndrome) with impaired proximal tubular function that may lead to glucosuria, tubular proteinuria (including generalized amino aciduria), renal tubular acidosis, hypokalemia, and hypouricemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4520?source=see_link&amp;anchor=H7#H7\">",
"     \"Renal involvement in the mitochondrial cytopathies\", section on 'Tubular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cytochrome c oxidase deficiency also can result in a benign reversible myopathy caused by a maternally inherited mutations (m.14674T&gt;C or m.14674T&gt;G) involving the mitochondrial transfer RNA for glutamic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11015/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The presentation of this condition is similar to that of the severe neonatal form. The condition is life-threatening in the first months after birth. Thereafter, infants improve biochemically and clinically over one to two years.",
"   </p>",
"   <p>",
"    Other presentations of cytochrome c oxidase deficiency have a more prominent encephalopathic component (eg, Leigh syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11015/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H21#H21\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Leigh syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mutations in the genes for several cytochrome c oxidase assembly factors have been demonstrated in some disorders, but the genetic defects in most remain unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11015/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The serum creatine kinase concentration may be slightly elevated in this disorder, although the electromyography usually is normal. Muscle biopsy shows nonspecific myopathic changes and ragged red fibers on Gomori trichrome staining, which is strong evidence for mitochondrial disease. Deficiency of cytochrome c oxidase is apparent on histochemical staining. Electron microscopy reveals accumulation of lipid and glycogen and an increased number of large abnormal appearing mitochondria in the muscle fibers. The severe and benign conditions can be differentiated on muscle biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3375809\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Newborns with neuromuscular disorders often present with hypotonia and weakness. These disorders are caused by a variety of conditions that affect the central nervous system, peripheral nervous system, or skeletal muscle. Conditions that affect the last two sites are reviewed briefly here (",
"      <a class=\"graphic graphic_table graphicRef66572 \" href=\"UTD.htm?27/44/28365\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Degeneration of the anterior horn cells of the spinal cord can occur in spinal muscular atrophy, traumatic myelopathy, hypoxic-ischemic myelopathy, and neurogenic arthrogryposis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anterior horn cell disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Congenital neuropathies can cause hypotonia and weakness that present during the neonatal period or early infancy. The most important of these conditions are the congenital motor sensory neuropathies and the hereditary sensory and autonomic neuropathies. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Congenital neuropathies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disorders of the neuromuscular junction are characterized by abnormal neuromuscular transmission, leading to muscle fatigability and weakness. These rare conditions include transient acquired neonatal myasthenia, congenital myasthenia, toxicity caused by magnesium or aminoglycosides, and infant botulism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=see_link\">",
"       \"Neuromuscular junction disorders in newborns and infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital myopathies are primary muscle disorders that are present from birth, although their expression may be delayed until later in infancy or childhood. They present with hypotonia and weakness that is greater proximally than distally. The most common diseases are nemaline myopathy, central core disease, myotubular myopathy, congenital fiber type disproportion, and multicore myopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13417?source=see_link\">",
"       \"Congenital myopathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The muscular dystrophies are an inherited group of progressive myopathic disorders resulting from defects in numerous genes required for normal muscle function. Some present in the newborn period (",
"      <a class=\"graphic graphic_table graphicRef66572 \" href=\"UTD.htm?27/44/28365\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Muscular dystrophies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain inborn errors of metabolism can present with progressive muscular hypotonia and weakness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      acute muscle dysfunction with muscle breakdown or myoglobinuria. These conditions include disorders of glycogen, lipid, peroxisomal, creatine, and mitochondrial metabolism. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Inborn errors of metabolism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11015/abstract/1\">",
"      Stromberger C, Bodamer OA, St&ouml;ckler-Ipsiroglu S. Clinical characteristics and diagnostic clues in inborn errors of creatine metabolism. J Inherit Metab Dis 2003; 26:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11015/abstract/2\">",
"      Mercimek-Mahmutoglu S, Stoeckler-Ipsiroglu S, Adami A, et al. GAMT deficiency: features, treatment, and outcome in an inborn error of creatine synthesis. Neurology 2006; 67:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11015/abstract/3\">",
"      Tritschler HJ, Bonilla E, Lombes A, et al. Differential diagnosis of fatal and benign cytochrome c oxidase-deficient myopathies of infancy: an immunohistochemical approach. Neurology 1991; 41:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11015/abstract/4\">",
"      DiMauro S, Lombes A, Nakase H, et al. Cytochrome c oxidase deficiency. Pediatr Res 1990; 28:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11015/abstract/5\">",
"      Salo MK, Rapola J, Somer H, et al. Reversible mitochondrial myopathy with cytochrome c oxidase deficiency. Arch Dis Child 1992; 67:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11015/abstract/6\">",
"      Wada H, Woo M, Nishio H, et al. Vascular involvement in benign infantile mitochondrial myopathy caused by reversible cytochrome c oxidase deficiency. Brain Dev 1996; 18:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11015/abstract/7\">",
"      Horvath R, Kemp JP, Tuppen HA, et al. Molecular basis of infantile reversible cytochrome c oxidase deficiency myopathy. Brain 2009; 132:3165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11015/abstract/8\">",
"      Mimaki M, Hatakeyama H, Komaki H, et al. Reversible infantile respiratory chain deficiency: a clinical and molecular study. Ann Neurol 2010; 68:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11015/abstract/9\">",
"      Shoubridge EA. Cytochrome c oxidase deficiency. Am J Med Genet 2001; 106:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11015/abstract/10\">",
"      Robinson BH. Human cytochrome oxidase deficiency. Pediatr Res 2000; 48:581.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6151 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_48_11015=[""].join("\n");
var outline_f10_48_11015=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3375809\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTERIOR HORN CELL DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Spinal muscular atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Traumatic myelopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hypoxic-ischemic myelopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Arthrogryposis multiplex congenita",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CONGENITAL NEUROPATHIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Congenital motor sensory neuropathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hereditary sensory and autonomic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NEUROMUSCULAR JUNCTION DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CONGENITAL MYOPATHIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MUSCULAR DYSTROPHIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dystrophinopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Congenital muscular dystrophies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Facioscapulohumeral muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Congenital myotonic dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      INBORN ERRORS OF METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Disorders of glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Primary carnitine deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Disorders of creatine metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Mitochondrial myopathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Cytochrome c oxidase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3375809\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6151\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6151|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/44/28365\" title=\"table 1\">",
"      Newborn neuromuscular disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/8/2187\" title=\"table 2\">",
"      HSANs in newborns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34004?source=related_link\">",
"      Approach to the infant with hypotonia and weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=related_link\">",
"      Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13417?source=related_link\">",
"      Congenital myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/34/26153?source=related_link\">",
"      Facioscapulohumeral muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=related_link\">",
"      Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43272?source=related_link\">",
"      Hereditary sensory and autonomic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=related_link\">",
"      Inborn errors of metabolism: Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17736?source=related_link\">",
"      Lysosomal acid maltase deficiency (glycogen storage disease II, Pompe disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=related_link\">",
"      Mitochondrial myopathies: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=related_link\">",
"      Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/10/166?source=related_link\">",
"      Neuromuscular junction disorders in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=related_link\">",
"      Oculopharyngeal, distal, and congenital muscular dystrophies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=related_link\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4520?source=related_link\">",
"      Renal involvement in the mitochondrial cytopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=related_link\">",
"      Spinal muscular atrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_48_11016="Prevention of anthrax";
var content_f10_48_11016=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of anthrax",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/48/11016/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11016/contributors\">",
"     Kenneth H Wilson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/48/11016/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11016/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/48/11016/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11016/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/48/11016/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of anthrax in humans has decreased during the past century, and it is now very rare in developed countries including the United States. From 1980 through 2000, only seven cases of anthrax were reported to the United States Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/1\">",
"     1",
"    </a>",
"    ]. However, in 2001, 22 confirmed or suspected anthrax cases occurred in the United States after Bacillus anthracis spores were sent through the mail in powder-containing envelopes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sporadic cases of inhalation and cutaneous anthrax also occurred between 2006 and 2008 in persons using contaminated imported animal hides for drum making, including two cases of cutaneous anthrax in the United States in a drum maker and a family member [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Both cutaneous and inhalation anthrax have also been associated with the playing of goatskin drums contaminated with B. anthracis spores [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39079?source=see_link&amp;anchor=H10#H10\">",
"     \"Microbiology, pathogenesis, and epidemiology of anthrax\", section on 'Bioterrorism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39079?source=see_link&amp;anchor=H9#H9\">",
"     \"Microbiology, pathogenesis, and epidemiology of anthrax\", section on 'Natural infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spores can persist in the soil for years to decades. Decontamination of the soil is generally not practical; thus, sporadic cases of epizootic anthrax continue to occur in areas of high endemicity, such as Iran, Iraq, Turkey, Pakistan, and sub-Saharan Africa, where the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=see_link\">",
"     anthrax vaccine",
"    </a>",
"    in animals is not comprehensive. Animals become infected with B. anthracis by ingesting spores while grazing on contaminated grass or feed. Naturally-occurring transmission to humans occurs through direct exposure to infected animals or animal products through skin exposure, ingestion, or inhalation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39079?source=see_link&amp;anchor=H9#H9\">",
"     \"Microbiology, pathogenesis, and epidemiology of anthrax\", section on 'Natural infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevention of anthrax will be reviewed here. The pathogenesis, epidemiology, clinical manifestations, diagnosis, and treatment of anthrax are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39079?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of anthrax\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7224?source=see_link\">",
"     \"Clinical manifestations and diagnosis of anthrax\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32232?source=see_link\">",
"     \"Treatment of anthrax\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of naturally-occurring anthrax in humans is primarily dependent on the control of the disease in animals, especially livestock. Animal vaccination is the major means of preventing naturally-occurring epizootics of anthrax, since widespread decontamination of infected soil is impractical. Annual vaccination of livestock in areas with enzootic anthrax is recommended.",
"   </p>",
"   <p>",
"    In the event of a naturally-occurring cutaneous exposure, such as from handling an anthrax-affected animal or its carcass, appropriate medical and public health personnel should be notified and exposed persons should be monitored for development of a spot, pimple, or boil, especially in the exposed areas. For naturally-occurring gastrointestinal exposure, such as the consumption of meat from a poorly cooked carcass of an anthrax-affected animal, antimicrobial prophylaxis may be considered for a 7 to 14 day period [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/8\">",
"     8",
"    </a>",
"    ]. Antimicrobial choices are the same as those recommended for PEP to prevent inhalation anthrax. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Postexposure prophylaxis'",
"    </a>",
"    below.) Vaccination is not recommended following either naturally occurring cutaneous or gastrointestinal exposure in which there is no risk of inhalation exposure.",
"   </p>",
"   <p>",
"    The United States Advisory Committee on Immunization Practices (ACIP) recommends the human",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=see_link\">",
"     anthrax vaccine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=see_link\">",
"     anthrax vaccine adsorbed",
"    </a>",
"    (AVA), for use prior to the occurrence of an event or exposure, as well as for post-exposure prophylaxis for inhalation anthrax in combination with antimicrobial therapy; these recommendations were updated in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Anthrax vaccine in the pre-event/pre-exposure setting'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H23\">",
"     'Postexposure prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Anthrax vaccine in the pre-event/pre-exposure setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=see_link\">",
"     Anthrax vaccine adsorbed",
"    </a>",
"    (AVA; BioThrax, Emergent BioSolutions, Rockville, MD) is the only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=see_link\">",
"     anthrax vaccine",
"    </a>",
"    licensed for human use in the United States, and is available from the manufacturer, Emergent BioSolutions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/8\">",
"     8",
"    </a>",
"    ]. A similar, protective antigen-based vaccine was tested in a field trial and shown to be highly effective in preventing inhalation and cutaneous anthrax in wool mill workers at risk for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/9\">",
"     9",
"    </a>",
"    ]. The recommended pre-event vaccination schedule for those at increased risk of exposure is complex since AVA was licensed originally for use as a six-dose, subcutaneously administered series. The use of AVA as part of the post-exposure prophylaxis regimen involves a shortened vaccination schedule and is discussed below. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Postexposure prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Given the complexity of the AVA administration schedule and the perceived high rate of injection site reactions when administered subcutaneously, a randomized noninferiority trial was performed to assess the immunogenicity of a reduced number of doses and administration via the intramuscular route [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/10\">",
"     10",
"    </a>",
"    ]. In the trial, 1563 volunteers were randomly assigned to one of six groups: AVA subcutaneously on the licensed six-dose schedule; AVA intramuscularly on the licensed six-dose schedule; AVA intramuscularly on one of three reduced dose schedules, or saline placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/10\">",
"     10",
"    </a>",
"    ]. A midpoint analysis of the first 1005 participants who received the first four doses of vaccine through month 7 was performed. Immunogenicity at month 7 was non-inferior for groups receiving either three (0, 4 weeks, and 6 months) or four (0, 2, 4 weeks, and 6 months) intramuscular injections. There was also a significantly lower incidence and severity of injection site adverse effects for the intramuscular route compared to the subcutaneous route.",
"   </p>",
"   <p>",
"    Based on these data, in December 2008 the FDA approved a new schedule for AVA. This new schedule for pre-exposure immunization calls for a series of five intramuscular injections administered at 0 and 4 weeks, and at 6, 12, and 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. To maintain immunity, an annual booster injection is recommended (",
"    <a class=\"graphic graphic_table graphicRef68056 \" href=\"UTD.htm?19/15/19707\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In October 2008, the ACIP voted to accept the following recommendations for the pre-event use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=see_link\">",
"     anthrax vaccine",
"    </a>",
"    among persons considered to be at risk for exposure to aerosolized B. anthracis spores [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. These recommendations include new language to address emergency responders, in addition to the previously approved recommended populations (",
"    <a class=\"graphic graphic_table graphicRef79398 \" href=\"UTD.htm?15/20/15693\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Selected persons who handle animals or animal products:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Veterinarians and other high-risk persons only if handling potentially infected animals or in areas with a high incidence of anthrax cases in animals",
"     </li>",
"     <li>",
"      Persons working in high-risk industries, such as those processing imported animal hides, hair, or wool for whom improved industrial hygiene standards and restrictions are insufficient to prevent exposure to anthrax spores",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratorians:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Those at risk for repeated exposures to B. anthracis spores including those who work with preparations of B. anthracis spores, handle environmental samples associated with anthrax investigations, routinely work with pure cultures of B. anthracis, or frequently work in spore-contaminated areas or other settings where repeated exposure to aerosols may occur",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Environmental",
"      <span class=\"nowrap\">",
"       investigators/remediation",
"      </span>",
"      workers:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Persons who, as part of their occupation, may enter areas contaminated with B. anthracis-spores",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Certain emergency and other responders:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Emergency and other responders are",
"      <strong>",
"       not",
"      </strong>",
"      recommended for routine pre-event anthrax vaccination, but units engaged in response activities that may lead to exposure to aerosolized B. anthracis spores may choose to offer their workers pre-event vaccination on a voluntary basis under the direction of a comprehensive occupational health and safety program",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Certain military personnel:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Military personnel determined by the United States Department of Defense to have a calculable risk of exposure to aerosolized B. anthracis spores are recommended to receive pre-event vaccination",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further details regarding the target groups are included in the Table (",
"    <a class=\"graphic graphic_table graphicRef79398 \" href=\"UTD.htm?15/20/15693\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cohort study of 4092 women found no difference in pregnancy rate or odds of having a live birth in women who received at least one dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=see_link\">",
"     anthrax vaccine",
"    </a>",
"    compared to those who had not [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/13\">",
"     13",
"    </a>",
"    ]. The study, however, was not powered sufficiently to determine whether there was an effect on birth outcomes.",
"   </p>",
"   <p>",
"    An additional study of 115,169 infants born to military women inadvertently vaccinated with AVA during pregnancy indicated that infants born to women receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=see_link\">",
"     anthrax vaccine",
"    </a>",
"    in their first trimester could have a slightly higher risk of birth defects compared to infants born to women receiving anthrax vaccine outside of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/14\">",
"     14",
"    </a>",
"    ]. The statistically significant finding was small and was not present when the comparison was made using women vaccinated during the second or third trimester. In addition, no overall pattern or type of birth defect was found in association with receipt of maternal anthrax vaccination.",
"   </p>",
"   <p>",
"    Consistent with the general practice of avoiding unnecessary exposure to vaccinations during pregnancy, pre-event vaccination is avoided in women who are known to be pregnant. However, in a post-exposure situation the risk of developing inhalation anthrax outweighs any potential risk vaccination may carry and exposed women should receive vaccination as a component of post-exposure prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vaccine development",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Sterne vaccine is a live, toxigenic, unencapsulated, avirulent vaccine strain that is widely used as a veterinary vaccine and has been responsible for much of the success in controlling anthrax in animals worldwide. Live spore vaccines analogous to the Sterne vaccine have been used for human immunization in Russia and China [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/15\">",
"     15",
"    </a>",
"    ], and are considered to be highly effective [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, in most countries live spore vaccines are not considered safe for human use due to safety concerns, such as necrosis at the inoculation site.",
"   </p>",
"   <p>",
"    A recombinant protective antigen (rPA) vaccine has demonstrated efficacy in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Phase 1, dose escalation human clinical trials were conducted comparing rPA to AVA for reactogenicity and immunogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The immune responses of participants receiving rPA with adjuvant were not statistically significantly different from those receiving AVA. However, problems with the vaccine formulation have delayed the start of phase III trials, and licensure will likely not occur for several years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Infection control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected or confirmed anthrax infection should be placed on standard precautions, which includes the routine use of gloves for contact with nonintact skin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/23\">",
"     23",
"    </a>",
"    ]. Appropriate personal protective equipment should be used when generation of aerosols or splatter of body fluids is anticipated, including during post-mortem care.",
"   </p>",
"   <p>",
"    Transmission can occur through direct contact with skin lesions. Private room placement is not necessary since airborne transmission does not occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of B. anthracis infection caused by bioterrorism, the United States Centers for Disease Control and Prevention has recommended the following measures for decontamination of patients and the surrounding environment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Instructing patients to remove contaminated clothing and store in labeled plastic bags",
"     </li>",
"     <li>",
"      Handling clothing minimally to avoid agitation",
"     </li>",
"     <li>",
"      Instructing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      assisting patients to shower thoroughly with soap and water",
"     </li>",
"     <li>",
"      Instructing health care and other emergency response personnel regarding standard precautions and using appropriate personal protective equipment (eg, gloves, gown, and respiratory protection) when handling contaminated clothing or other potentially contaminated fomites",
"     </li>",
"     <li>",
"      Decontaminating environmental surfaces using 0.5 percent hypochlorite solution (one part bleach added to nine parts water) or another approved",
"      <span class=\"nowrap\">",
"       sporicidal/germicidal",
"      </span>",
"      agent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22247?source=see_link&amp;anchor=H16715275#H16715275\">",
"     \"Identifying and managing casualties of biological terrorism\", section on 'Decontamination (overt exposure)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     POSTEXPOSURE PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postexposure prophylaxis for inhalation anthrax (IA) involves antibiotics and vaccination.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32755?source=see_link\">",
"     Raxibacumab",
"    </a>",
"    , a monoclonal antibody against protective antigen, can be used when alternative preventive therapies are not available or are not appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     PEP antibiotic regimens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Primate studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies of experimental IA in monkeys showed that treatment with penicillin beginning one day after aerosol exposure to B. anthracis spores was protective during the 5 to 10 days of drug therapy; however, the animals died when penicillin was discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a subsequent report of experimental IA, monkeys were challenged with aerosolized B. anthracis spores; 24 hours later three groups of animals were treated with either penicillin, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    for 30 days, and a fourth group received the combination of doxycycline and the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=see_link\">",
"     anthrax vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/25\">",
"     25",
"    </a>",
"    ]. The 30 day antimicrobial treatment regimens completely protected animals while they were on therapy; post-treatment survival in animals given only antimicrobial therapy ranged from 70 to 90 percent compared with 100 percent survival in animals given antimicrobial therapy plus vaccine. However, when the monkeys were rechallenged with airborne B. anthracis spores, all animals died except for those that had been immunized.",
"   </p>",
"   <p>",
"    A third study in monkeys compared a 14 day course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    with the combination of a 14 day regimen of ciprofloxacin plus three doses of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=see_link\">",
"     anthrax vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/26\">",
"     26",
"    </a>",
"    ]. Only 44 percent of animals receiving 14 days of antimicrobial therapy alone survived compared with 100 percent survival among animals given both antimicrobial therapy and the anthrax vaccine. These data offer evidence that the use of post-exposure antimicrobial prophylaxis combined with active immunization provides effective protection against the development of IA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Humans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three oral antimicrobial agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ) have been approved by the United States Food and Drug Administration (FDA) and are recommended by CDC for anthrax post-exposure prophylaxis (PEP). The recommended duration of PEP antimicrobial therapy is 60 days (",
"    <a class=\"graphic graphic_table graphicRef58905 \" href=\"UTD.htm?22/51/23357\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      are approved for use in adults and children, and are considered equivalent first-line antimicrobial agents for inhalation anthrax PEP [",
"      <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/8\">",
"       8",
"      </a>",
"      ]. The recommended dosing is as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (500 mg twice daily in adults; 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily [not to exceed 500",
"      <span class=\"nowrap\">",
"       mg/dose]",
"      </span>",
"      in children)",
"      <br/>",
"      <br/>",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg twice daily in adults; in children &gt;8 yrs and &gt;45 kg: 100 mg twice daily; in children &gt;8 yrs and &le;45 kg: 2.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily; in children &le;8 years: 2.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily [not to exceed 100",
"      <span class=\"nowrap\">",
"       mg/dose])",
"       <br/>",
"       <br/>",
"       <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"        Ciprofloxacin",
"       </a>",
"      </span>",
"      is considered the first-line drug for PEP in pregnant women and nursing mothers [",
"      <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/8,27-29\">",
"       8,27-29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      is also FDA-approved for inhalation anthrax PEP in adults and children &ge;6 months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. However, levofloxacin is considered a second-line antimicrobial agent for PEP when medical issues such as tolerance or resistance may call for its use, since safety data on the use of levofloxacin for more than 28 days are limited [",
"      <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/8\">",
"       8",
"      </a>",
"      ]. The recommended dosing is as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      (500 mg once daily in adults and children &gt;50 kg; 8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily [not to exceed 500",
"      <span class=\"nowrap\">",
"       mg/day]",
"      </span>",
"      in children &ge;6 months of age and &lt;50 kg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adverse events (eg, gastrointestinal distress) associated with long-term use of antimicrobial agents are to be expected and should be evaluated. Clinicians and public health personnel should be aware when prescribing fluoroquinolones for long-term use that they have been associated with tendinitis and tendon rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link&amp;anchor=H29#H29\">",
"     \"Fluoroquinolones\", section on 'Tendinopathy and tendon rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians may choose to use oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (500 mg every 8 hours in adults; 45",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided every 8 hours [not to exceed 500",
"    <span class=\"nowrap\">",
"     mg/dose]",
"    </span>",
"    in children) as an alternative for PEP for certain patient groups (eg, pediatric patients, pregnant or nursing women) when other agents are not considered as safe to use and if the associated B. anthracis strain has an amoxicillin MIC &le;0.125",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. However, amoxicillin has not been approved for anthrax PEP by the FDA.",
"   </p>",
"   <p>",
"    For patients unable to tolerate FDA-approved antimicrobial agents, clinicians may consider",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , fluoroquinolones (other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    as alternatives for PEP, based on in vitro susceptibility results. However, data supporting the use of these antibiotics are lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2001, approximately 10,000 individuals were offered 60 days of antimicrobial PEP therapy for the prevention of inhalation anthrax (IA) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/35\">",
"     35",
"    </a>",
"    ]. Anaphylactoid reactions were reported within 30 days in four persons who received antimicrobial PEP. Overall, 3032 of 5343 individuals (57 percent) who took at least one antimicrobial prophylactic dose reported clinical symptoms; most of these were mild. The most common adverse events were gastrointestinal (44 percent) and neurologic (33 percent); 16 percent of patients sought medical care for adverse events.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=see_link\">",
"     Anthrax Vaccine",
"    </a>",
"    and Antibiotic Availability Program (AVAAP) offered extended antimicrobial PEP (&gt;60 days) for persons at risk of IA, and 1727 individuals received anthrax vaccine in addition to extended antimicrobial PEP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/36\">",
"     36",
"    </a>",
"    ]. Three serious adverse events with a probable or possible relationship to the AVAAP protocol were identified: one case of allergic interstitial nephritis was classified as likely causally related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    PEP, and two serious adverse events were determined to be possibly related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    PEP. No serious adverse events were associated with anthrax vaccine use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Vaccine for PEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=see_link\">",
"     Anthrax vaccine adsorbed",
"    </a>",
"    (AVA) is recommended by ACIP and CDC as part of the PEP regimen for inhalation anthrax (IA) exposure and is available from the",
"    <a class=\"external\" href=\"file://www.cdc.gov/\">",
"     CDC",
"    </a>",
"    , through the state and local health departments, as part of an Investigational New Drug (IND) protocol.",
"   </p>",
"   <p>",
"    In the post-exposure setting, ACIP recommends that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=see_link\">",
"     anthrax vaccine",
"    </a>",
"    be administered in three subcutaneous doses (at zero, two, and four weeks) in conjunction with a 60 day course of antimicrobial therapy (",
"    <a class=\"graphic graphic_table graphicRef68056 \" href=\"UTD.htm?19/15/19707\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58905 \" href=\"UTD.htm?22/51/23357\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/8\">",
"     8",
"    </a>",
"    ]. In order to maximize the benefits of the vaccine, it should be offered within 10 days of exposure. ACIP recommends the use of AVA for both pregnant and lactating women exposed to aerosolized B. anthracis spores, as well as the consideration of vaccine use among children exposed to B. anthracis spores [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/8\">",
"     8",
"    </a>",
"    ]. State and local health departments should be immediately notified in the event of suspicion of exposure to anthrax and for any requests for anthrax vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64397865\">",
"    <span class=\"h2\">",
"     Raxibacumab and other immunotherapeutics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32755?source=see_link\">",
"     Raxibacumab",
"    </a>",
"    is a human IgG1-gamma monoclonal antibody directed against protective antigen (PA). In 2012, raxibacumab was approved by the US Food and Drug Administration for the prevention of inhalation anthrax when alternative preventive therapies are not available or are not appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. A supply of raxibacumab is held in the United States Strategic National Stockpile for use by the CDC in the event of an anthrax emergency [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/38\">",
"     38",
"    </a>",
"    ]. Clinicians should contact the",
"    <a class=\"external\" href=\"file://www.cdc.gov/\">",
"     CDC",
"    </a>",
"    if raxibacumab is indicated.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32755?source=see_link\">",
"     Raxibacumab",
"    </a>",
"    is given as a single dose following premedication with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ; dosing recommendations for raxibacumab are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adults and children &gt;50 kg: 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV",
"     </li>",
"     <li>",
"      Children 15 kg to 50 kg: 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV",
"     </li>",
"     <li>",
"      Children 15 kg or less: 80",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32755?source=see_link\">",
"     raxibacumab",
"    </a>",
"    has been evaluated only in animals since it is not possible to perform efficacy trials in humans given that inhalation anthrax is both rare and lethal. However, in phase 2 safety studies in humans, the therapeutic levels of the antibody achieved in humans are equal to or greater than those that provide protection in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/40\">",
"     40",
"    </a>",
"    ]. Common adverse effects in 326 healthy humans included rash, extremity pain, pruritus, and drowsiness [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both rabbits and monkeys had significantly improved survival when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32755?source=see_link\">",
"     raxibacumab",
"    </a>",
"    , a human monoclonal antibody directed against PA, was administered immediately following an aerosolized challenge with B. anthracis spores [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/41\">",
"     41",
"    </a>",
"    ]. Among rabbits that received subcutaneous or intravenous raxibacumab, 80 to 100 percent survived to 14 days (depending on the dose) compared with 0 percent in those that received placebo. Among monkeys, 90 percent of those that received 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of raxibacumab subcutaneously survived to 28 days compared with 0 percent of those that received placebo. All monkeys that were rechallenged with anthrax spores approximately one year following raxibacumab administration were protected from infection, whereas all monkeys that received placebo died following rechallenge. In the same report, raxibacumab was also highly effective for the treatment of anthrax. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32232?source=see_link&amp;anchor=H1061471327#H1061471327\">",
"     \"Treatment of anthrax\", section on 'Raxibacumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32755?source=see_link\">",
"     raxibacumab",
"    </a>",
"    in mice, guinea pigs, and rabbits, efficacy decreased as time from exposure to B. anthracis spores to raxibacumab administration increased beyond 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immune serum containing B. anthracis antibodies has also been evaluated for PEP. In animal studies, passive immunization within 24 hours post-exposure with immune serum containing antibodies against the B. anthracis PA has conferred some degree of protection against an intranasal live spore challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/43\">",
"     43",
"    </a>",
"    ]. The efficacy of passive immunization used for prophylaxis has not been studied throughout the entire duration of PEP (60 days following exposure), and protection conferred by antiserum prophylaxis begins to decrease at approximately 3 weeks following the first dose [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11016/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sporadic cases and outbreaks of naturally-occurring anthrax continue to occur worldwide, although they are relatively rare in developed nations. However, the threat of anthrax resulting from bioterrorism activity is a reality. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Animal vaccination against anthrax is the major means of preventing naturally-occurring anthrax in humans. Vaccination of persons likely to have occupational exposures to aerosolized B. anthracis spores is the best method for prevention of anthrax among those at highest risk. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Post-exposure prophylaxis (PEP) is recommended for individuals at risk of inhalation anthrax (",
"      <a class=\"graphic graphic_table graphicRef79398 \" href=\"UTD.htm?15/20/15693\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral PEP regimens include one of the following in both adults and children (",
"      <a class=\"graphic graphic_table graphicRef58905 \" href=\"UTD.htm?22/51/23357\">",
"       table 3",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      monotherapy and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      monotherapy are considered equivalent first-line antimicrobial agents for PEP.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      is considered a second-line antimicrobial agent for PEP where medical issues such as tolerance or resistance may call for its use, as safety data on extended use of levofloxacin is limited. Levofloxacin is approved for children &ge;6 months of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      is the first-line drug for PEP in pregnant women and nursing mothers. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'PEP antibiotic regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians may choose to use oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      as an alternative for PEP for certain patient groups (eg, children, pregnant or nursing women) if the associated B. anthracis strain has an amoxicillin MIC &le;0.125",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      (see",
"      <a class=\"local\" href=\"#H24\">",
"       'PEP antibiotic regimens'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The recommended duration of PEP antimicrobial therapy is 60 days. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'PEP antibiotic regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In conjunction with antimicrobial PEP, vaccination with the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=see_link\">",
"       anthrax vaccine adsorbed",
"      </a>",
"      in three subcutaneous doses (at zero, two and four weeks) is recommended by the United States Advisory Committee on Immunization Practices and the United States Centers for Disease Control and Prevention (CDC) as part of the PEP regimen for postexposure prophylaxis for inhalation anthrax exposure (",
"      <a class=\"graphic graphic_table graphicRef68056 \" href=\"UTD.htm?19/15/19707\">",
"       table 1",
"      </a>",
"      ). The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=see_link\">",
"       anthrax vaccine",
"      </a>",
"      absorbed is available from the",
"      <a class=\"external\" href=\"file://www.cdc.gov/\">",
"       CDC",
"      </a>",
"      , through state and local health departments. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Vaccine for PEP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32755?source=see_link\">",
"       Raxibacumab",
"      </a>",
"      , a human monoclonal antibody against protective antigen, should be used for the prevention of inhalation anthrax when alternative preventive therapies are not available or are not appropriate. Clinicians should contact the",
"      <a class=\"external\" href=\"file://www.cdc.gov/\">",
"       CDC",
"      </a>",
"      if raxibacumab is indicated. (See",
"      <a class=\"local\" href=\"#H64397865\">",
"       'Raxibacumab and other immunotherapeutics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of anthrax is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32232?source=see_link\">",
"       \"Treatment of anthrax\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/1\">",
"      Hopkins RS, Jajosky RA, Hall PA, et al. Summary of notifiable diseases--United States, 2003. MMWR Morb Mortal Wkly Rep 2005; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/2\">",
"      Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002; 8:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/3\">",
"      Lightfoot N, Scott R, Turnbull B. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med Bull Suppl 1990; 68:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/4\">",
"      Do��anay M, Aydin N. Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis 1991; 23:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/5\">",
"      Turnbull PC, Sirianni NM, LeBron CI, et al. MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol 2004; 42:3626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/6\">",
"      Luna VA, King DS, Gulledge J, et al. Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre automated microbroth dilution and Etest agar gradient diffusion methods. J Antimicrob Chemother 2007; 60:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/7\">",
"      Bakici MZ, Elaldi N, Bakir M, et al. Antimicrobial susceptibility of Bacillus anthracis in an endemic area. Scand J Infect Dis 2002; 34:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/8\">",
"      Wright JG, Quinn CP, Shadomy S, et al. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/9\">",
"      Brachman PS, Gold H, Plotkin SA, et al. Field Evaluation of a Human Anthrax Vaccine. Am J Public Health Nations Health 1962; 52:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/10\">",
"      Marano N, Plikaytis BD, Martin SW, et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 2008; 300:1532.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. Biothrax Product Approval Information. 2008. file://www.fda.gov/cber/approvltr/biothrax121108L.htm (Accessed on February 13, 2009).",
"    </li>",
"    <li>",
"     Centers for Disease Control And Prevention. Summary Report of the Meeting of the Advisory Committee on Immunization Practices (ACIP), October 22-23. Atlanta, GA 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/13\">",
"      Wiesen AR, Littell CT. Relationship between prepregnancy anthrax vaccination and pregnancy and birth outcomes among US Army women. JAMA 2002; 287:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/14\">",
"      Ryan MA, Smith TC, Sevick CJ, et al. Birth defects among infants born to women who received anthrax vaccine in pregnancy. Am J Epidemiol 2008; 168:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/15\">",
"      Turnbull PC. Current status of immunization against anthrax: old vaccines may be here to stay for a while. Curr Opin Infect Dis 2000; 13:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/16\">",
"      Shlyakhov EN, Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine 1994; 12:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/17\">",
"      Donegan S, Bellamy R, Gamble CL. Vaccines for preventing anthrax. Cochrane Database Syst Rev 2009; :CD006403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/18\">",
"      McBride BW, Mogg A, Telfer JL, et al. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 1998; 16:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/19\">",
"      Miller J, McBride BW, Manchee RJ, et al. Production and purification of recombinant protective antigen and protective efficacy against Bacillus anthracis. Lett Appl Microbiol 1998; 26:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/20\">",
"      Ivins BE, Pitt ML, Fellows PF, et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 1998; 16:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/21\">",
"      Gorse GJ, Keitel W, Keyserling H, et al. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 2006; 24:5950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/22\">",
"      Campbell JD, Clement KH, Wasserman SS, et al. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccin 2007; 3:205.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Bioterrorism readiness plan: a template for healthcare facilities. file://www.cdc.gov/ncidod/dhqp/pdf/bt/13apr99APIC-CDCBioterrorism (Accessed on October 06, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/24\">",
"      GOCHENOUR WS Jr, GLEISER CA, TIGERTT WD. Observations on penicillin prophylaxis of experimental inhalation anthrax in the monkey. J Hyg (Lond) 1962; 60:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/25\">",
"      Friedlander AM, Welkos SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993; 167:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/26\">",
"      Vietri NJ, Purcell BK, Lawler JV, et al. Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci U S A 2006; 103:7813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Update: Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR Morb Mortal Wkly Rep 2001; 50:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/28\">",
"      ACOG Committee on Obstetric Practice. ACOG Committee Opinion number 268, February 2002. Management of asymptomatic pregnant or lactating women exposed to anthrax. American College of Obstetricians and Gynecologists. Obstet Gynecol 2002; 99:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/29\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis. MMWR Morb Mortal Wkly Rep 2001; 50:960.",
"     </a>",
"    </li>",
"    <li>",
"     Ortho-McNeil Pharmaceutical. Product insert, Levaquin (Levofloxacin) tablets. 2004.",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Supplemental New Drug Application Approval (NDA 20-634/S-047; NDA 20-635/S-051; NDA 21-721/S-015). 2008. file://www.fda.gov (Accessed on February 11, 2009).",
"    </li>",
"    <li>",
"     Food and Drug Administration. Information for Healthcare Professionals: Fluoroquinolone Antimicrobial Drugs. 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/33\">",
"      Cook PJ, Andrews JM, Woodcock J, et al. Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection. Thorax 1994; 49:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/34\">",
"      Weing&auml;rtner L, Sitka U, Patsch R, et al. Amoxicillin in paediatrics, with special reference to its excretion into bronchial secretion. Int J Clin Pharmacol Ther Toxicol 1980; 18:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/35\">",
"      Shepard CW, Soriano-Gabarro M, Zell ER, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 2002; 8:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/36\">",
"      Tierney BC, Martin SW, Franzke LH, et al. Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax. Clin Infect Dis 2003; 37:905.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA News Release. FDA approves raxibacumab to treat inhalational anthrax. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332341.htm (Accessed on January 02, 2013).",
"    </li>",
"    <li>",
"     Anti-Infective Drugs Advisory Committee Meeting - 02 November 2012. Human Genome Sciences, Inc. Briefing Document, Raxibacumab - ",
"Treatment of Inhalational Anthrax. BLA 125349. file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM326185.pdf (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     Raxibacumab prescribing information. file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125349s000lbl.pdf (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/40\">",
"      Nabel GJ. Protecting against future shock--inhalational anthrax. N Engl J Med 2009; 361:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/41\">",
"      Migone TS, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009; 361:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/42\">",
"      Peterson JW, Comer JE, Noffsinger DM, et al. Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun 2006; 74:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/43\">",
"      Kobiler D, Gozes Y, Rosenberg H, et al. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immun 2002; 70:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11016/abstract/44\">",
"      HENDERSON DW, PEACOCK S, BELTON FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond) 1956; 54:28.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5535 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-0ACB48A304-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_48_11016=[""].join("\n");
var outline_f10_48_11016=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Anthrax vaccine in the pre-event/pre-exposure setting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vaccine development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Infection control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Decontamination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      POSTEXPOSURE PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PEP antibiotic regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Primate studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Humans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Vaccine for PEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64397865\">",
"      Raxibacumab and other immunotherapeutics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5535\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5535|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/15/19707\" title=\"table 1\">",
"      Anthrax vaccine recs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/20/15693\" title=\"table 2\">",
"      Anthrax vaccine target groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/51/23357\" title=\"table 3\">",
"      Anthrax PEP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7224?source=related_link\">",
"      Clinical manifestations and diagnosis of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22247?source=related_link\">",
"      Identifying and managing casualties of biological terrorism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39079?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32232?source=related_link\">",
"      Treatment of anthrax",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_48_11017="Electrocardiographic changes during exercise ECG testing";
var content_f10_48_11017=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Electrocardiographic changes during exercise ECG testing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/48/11017/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11017/contributors\">",
"     Frank G Yanowitz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/48/11017/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11017/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11017/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/48/11017/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11017/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/48/11017/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exercise electrocardiogram (ECG) test is a popular, well-established, inexpensive procedure for answering important clinical questions related to exercise tolerance and heart disease. The exercise ECG test indirectly detects myocardial ischemia, the physiologic consequence of coronary obstruction. Myocardial ischemia (silent or symptomatic) occurs when there is a transient imbalance between myocardial oxygen delivery (coronary blood flow) and demand (myocardial work). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=see_link\">",
"     \"Pathophysiology and clinical presentation of ischemic chest pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary myocardial ischemia results when myocardial oxygen supply is interrupted by dynamic increases in coronary vasomotor tone (eg, spasm) or thrombus formation (eg, acute coronary syndrome) and is often independent of changes in myocardial oxygen demands.",
"     </li>",
"     <li>",
"      Secondary ischemia is due to factors that increase myocardial oxygen requirements. As an example, in the setting of significant fixed coronary artery obstruction, ischemia occurs during stressful events that increase heart rate, ventricular volume, blood pressure (ventricular pressure, wall tension), or myocardial contractility. The electrocardiographic response to exercise provides an indirect assessment of the adequacy of myocardial oxygen supply during periods of increased demand.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the type of ischemia, a well-recognized sequence of events is precipitated by an imbalance between myocardial oxygen supply and demand (",
"    <a class=\"graphic graphic_figure graphicRef79335 \" href=\"UTD.htm?32/60/33741\">",
"     figure 1",
"    </a>",
"    ). Echocardiographic studies carried out during coronary angioplasty have shown that regional wall motion abnormalities occur within 10 to 30 seconds, followed in order by decreased ejection fraction, increased end-diastolic pressure, ST segment abnormalities without pain, and finally angina pectoris [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This sequence helps explain why mechanical measures of ischemia obtained with ultrasound or gated blood-pool imaging are more sensitive indicators than ECG measures; they occur at a lower intensity of ischemia, and thereby precede ECG changes. Similarly, silent ischemia that is identified electrocardiographically often occurs at a lower ischemic threshold than that needed for the symptomatic expression of ischemia.",
"   </p>",
"   <p>",
"    The sensitivity and specificity of exercise ECG testing have been derived from studies correlating the ECG response to exercise with coronary angiographic data (to document the anatomic abnormality). Patient sex, age, coronary risk factors, and the characteristics of the chest pain are also important determinants of the pretest probability of coronary heart disease and therefore of the diagnostic accuracy of exercise ECG testing. Exercise ECG testing can also be used to estimate prognosis in patients with known coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ECG changes that occur during exercise testing in patients with coronary heart disease, which form the basis of the clinical utility of exercise ECG testing, will be reviewed here. The technique of exercise testing and indications and contraindications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ELECTROPHYSIOLOGY OF MYOCARDIAL ISCHEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrophysiologic consequences of myocardial ischemia are responsible for the typical ST-T wave abnormalities seen on the ECG during exercise testing in patients with coronary heart disease. Reviewed briefly, the QRS complex reflects the time sequence of ventricular depolarization as the activation front spreads through the myocardium (phase 0 of the action potential), (",
"    <a class=\"graphic graphic_figure graphicRef64133 \" href=\"UTD.htm?26/24/27023\">",
"     figure 2",
"    </a>",
"    ). The ST segment coincides with the plateau or phase 2 of ventricular repolarization, and the T wave reflects the time sequence of phase 3 repolarization. Phase 4, the resting membrane potential, is responsible for the TQ segment; this segment of the ECG is usually not considered to be important, but actually has a prominent role in the ECG manifestations of ischemia (see",
"    <a class=\"local\" href=\"#H4\">",
"     'ST segment depression'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Action potentials become markedly altered during localized myocardial ischemia. A depiction of the ischemic alterations in typical action potentials, recorded from subepicardial and ischemic subendocardial regions of the left ventricle, is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef72672 \" href=\"UTD.htm?13/45/14035\">",
"     figure 3",
"    </a>",
"    ). This is the usual clinical setting of exercise-induced ischemia, since the subendocardial regions supplied by critical coronary lesions are most vulnerable.",
"   </p>",
"   <p>",
"    Under normal conditions, the timing of the ST segment coincides with the plateaus of the two action potentials, which are at the same voltage, as in panel A (",
"    <a class=\"graphic graphic_figure graphicRef72672 \" href=\"UTD.htm?13/45/14035\">",
"     figure 3",
"    </a>",
"    ). The ST segment lies close to the isoelectric baseline since little current is flowing between the two regions during the plateau.",
"   </p>",
"   <p>",
"    During episodes of ischemia, however, two distinct currents of injury, systolic and diastolic, develop between ischemic and normal tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diastolic current of injury (as in panel B) is thought to be the more specific ischemic change (",
"      <a class=\"graphic graphic_figure graphicRef72672 \" href=\"UTD.htm?13/45/14035\">",
"       figure 3",
"      </a>",
"      ). In this example of subendocardial injury, ischemic cells experience a decrease in resting membrane potential because the injured cells no longer have the energy to maintain a &ndash;90 mV resting potential gradient across the cell membrane. Thus, current flows from the uninjured outer myocardium into the subendocardial region during phase 4 of the action potential (diastole). The TQ segment recorded from a closely placed ECG lead is displaced upwards, but is automatically shifted back to baseline by the capacitor-coupled amplifier of the ECG machine since the baseline shifts in the ECG signal are considered by the machine to be artifact. The return of the elevated TQ to baseline shifts the ST segment below baseline, thereby causing \"pseudo\" ST segment depression. The T wave remains positive because the direction of the potential gradient developed during late recovery is unchanged from normal.",
"     </li>",
"     <li>",
"      A systolic current of injury superimposed upon the previously described diastolic injury occurs when the injured subendocardial cells undergo a decreased amplitude of depolarization and shortened recovery, as in panel C (",
"      <a class=\"graphic graphic_figure graphicRef72672 \" href=\"UTD.htm?13/45/14035\">",
"       figure 3",
"      </a>",
"      ). This results in two ECG changes: true ST segment depression due to the potential gradient that has now developed during the plateau of the action potentials; and T wave inversion due to reversal of the direction of late repolarization between injured and uninjured regions of the left ventricle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Systolic and diastolic injury currents also occur between injured and uninjured cells when the injury involves the full thickness of left ventricular myocardium (eg, transmural injury) or just the subepicardial region (eg, pericarditis). However, these currents are in the reverse direction from those seen with subendocardial injury (",
"    <a class=\"graphic graphic_figure graphicRef73239 \" href=\"UTD.htm?2/14/2274\">",
"     figure 4",
"    </a>",
"    ). This results in TQ segment depression which is quickly restored to baseline, ST segment elevation, and large upright T waves. These are the same changes that are seen during the early stages of acute ST segment elevation myocardial infarction. When seen during exercise testing, however, they usually revert to normal as soon as the exercise is stopped.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ECG ABNORMALITIES DURING EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion shows that the most important ischemic ECG changes during exercise are related to shifts in the ST segment, both \"pseudo\" shifts and true shifts depending upon the specific currents of injury present. The full spectrum of the ischemic ECG involves changes in the ST segment, the T wave, and the U wave (",
"    <a class=\"graphic graphic_figure graphicRef80752 \" href=\"UTD.htm?20/13/20689\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These changes can be detected only in patients who do not have baseline ECG abnormalities that can interfere with interpretation. These baseline abnormalities include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preexcitation (Wolff-Parkinson-White) syndrome",
"     </li>",
"     <li>",
"      Complete left bundle branch block or related left ventricular intraventricular conduction delays",
"     </li>",
"     <li>",
"      Greater than 1 mm ST segment depression at rest",
"     </li>",
"     <li>",
"      Paced ventricular rhythm",
"     </li>",
"     <li>",
"      Repolarization abnormalities in a patient taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"     </li>",
"     <li>",
"      Left ventricular overload with repolarization changes",
"     </li>",
"     <li>",
"      Hypokalemia with repolarization abnormalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following discussion will review the ischemic ECG changes that can occur during and after exercise. Exercise protocols (",
"    <a class=\"graphic graphic_table graphicRef70044 \" href=\"UTD.htm?12/51/13118\">",
"     table 1",
"    </a>",
"    ) and the end points of testing (",
"    <a class=\"graphic graphic_table graphicRef77689 \" href=\"UTD.htm?14/28/14796\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53266 \" href=\"UTD.htm?2/19/2365\">",
"     table 3",
"    </a>",
"    ) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     ST segment depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression of the J point (end of the QRS and beginning of the ST segment) is normally seen with increasing heart rates during exercise (",
"    <a class=\"graphic graphic_figure graphicRef80752 \" href=\"UTD.htm?20/13/20689\">",
"     figure 5",
"    </a>",
"    ); it is probably related to atrial repolarization that extends through the QRS rather than myocardial ischemia. In this circumstance, the ST segment rapidly returns to baseline.",
"   </p>",
"   <p>",
"    Subendocardial ischemia during exercise produces ST segment depression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevation. The progression of ST segment depression is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upsloping ST depression appears first during exercise and is less specific for ischemia than horizontal ST depression (",
"      <a class=\"graphic graphic_figure graphicRef80752 \" href=\"UTD.htm?20/13/20689\">",
"       figure 5",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/5\">",
"       5",
"      </a>",
"      ]. Upsloping and horizontal ST depression are related to the diastolic current of injury involving the TQ segment of the ECG. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Electrophysiology of myocardial ischemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Horizontal or downsloping ST depression of &ge;1 mm (",
"      <a class=\"graphic graphic_waveform graphicRef56740 \" href=\"UTD.htm?19/48/20225\">",
"       waveform 1",
"      </a>",
"      ), often associated with T wave inversion, may be seen during exercise but is most often seen during recovery from exercise, and is probably related to both systolic and diastolic injury currents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sensitivity and specificity of ST depression vary with the criterion used to define an abnormal test. Test results that absolutely distinguish those with and without disease (ie, high specificity) are often not present in many patients with disease (low sensitivity). As an example, if a \"positive\" ECG result were defined as 3 mm ST segment depression rather than the usual criterion of 1 mm, the probability would be very high that all individuals without disease will have negative tests. Although this approach maximizes the specificity of the stress test, it substantially reduces sensitivity since very few patients with coronary heart disease will be detected. Conversely, the application of less stringent criteria for detection of disease would increase sensitivity but decrease specificity (",
"    <a class=\"graphic graphic_table graphicRef59283 \" href=\"UTD.htm?3/23/3451\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Leads V4, V5, and V6 are the most sensitive leads for detecting the ST depression of subendocardial ischemia; V5 alone is often the single best lead for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, ST depression in the lateral precordial leads does not localize the coronary artery responsible for the ischemic change in patients with normal resting ECGs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, ST segment depression confined to the inferior leads II and aVF is most often a false positive response, and is of little value in diagnosing coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/6\">",
"     6",
"    </a>",
"    ]. However, greater ST segment depression involving multiple leads usually signifies extensive myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Flat or downsloping ST depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis involving 24,000 patients attempted to define reasonable estimates for the diagnostic sensitivity and specificity of ST depression during the exercise ECG test [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/5\">",
"     5",
"    </a>",
"    ]. There was a wide variation in values for these parameters; the mean sensitivity was 68 percent but ranged from 23 to 100 percent, and the mean specificity was 77 percent but ranged from 17 to 100 percent. This wide range reflected different criteria for a positive test and bias in patient selection in most of the published literature. Nevertheless, when the criteria for a positive exercise ECG test were defined as &ge;1 mm horizontal or downsloping ST segment depression, the mean sensitivity and specificity was approximately 60 and 90 percent, respectively.",
"   </p>",
"   <p>",
"    The development of horizontal or downsloping ST depression after exercise also has prognostic significance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H3#H3\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Flat or downsloping ST depression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Upsloping ST depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data on the predictive value of slow rising (upsloping) ST depression. Initial studies suggested that patients with this finding had an increased likelihood of coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, although use of this criterion increases sensitivity, it also reduces specificity. The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines favor the standard criterion for a positive test of &ge;1 mm of downsloping or flat ST depression [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A report of 1083 asymptomatic patients published after the guidelines are consistent with this conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/12\">",
"     12",
"    </a>",
"    ]. Slowly rising ST depression with exercise occurred in 11.4 percent; the prognosis in these patients was not different from those with a normal exercise ECG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Resting ST depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;ST segment depression during exercise is",
"    <strong>",
"     not",
"    </strong>",
"    a reliable indicator of ischemia when the resting baseline ECG has ST segment depression due, for example, to a bundle branch block, left ventricular hypertrophy, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    therapy. However, ST segment depression on a resting ECG may be seen in patients with coronary disease in the absence of these factors. In such patients, a further increase in ST segment depression has diagnostic value in patients without or with a history of coronary disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated 1282 patients without a prior myocardial infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/13\">",
"       13",
"      </a>",
"      ]. The patients underwent standard exercise treadmill testing followed by coronary angiography. In patients with resting ST segment depression, the sensitivity of exercise testing was higher when compared to those without ST segment depression based upon either visual inspection (77 versus 45 percent) or computerized analysis (71 versus 42 percent). However, the specificity was lower (48 versus 84 percent and 52 versus 87 percent). The net effect is that there was no difference in the predictive accuracy in those with or without ST segment depression (68 and 65 versus 62 percent).",
"     </li>",
"     <li>",
"      Similar findings were noted in another report in which exercise testing and thallium perfusion imaging were performed in 882 patients within six months of a myocardial infarction or unstable angina [",
"      <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/14\">",
"       14",
"      </a>",
"      ]. The presence of baseline ST segment depression (&ge;0.5 mm) did not change the overall diagnostic accuracy of the exercise test (56 versus 58 percent for those without baseline ST segment depression), although there was a higher false positive rate (ie, lower specificity).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Exacerbation of minor degrees of resting ST depression during exercise also has prognostic value. This was illustrated in the above review of 1083 volunteers who were apparently free from coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/12\">",
"     12",
"    </a>",
"    ]. Minor resting ST depression (&lt;0.5 mm) that intensified to &ge;1 mm of flat or downsloping ST depression during or after exercise was an independent predictor of subsequent coronary risk (relative risk 2.73). In addition, the presence of nonspecific ST-T abnormalities on a resting ECG does not interfere with use of the Duke treadmill score to estimate prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Risk scores'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treadmill exercise testing has a higher false-positive rate in women than men, and both positive and negative tests have relatively low predictive value. In addition, a report from the Lipid Clinics Research Study suggested that the prognostic value of exercise testing in women without known or suspected coronary disease may be unrelated to ST changes suggestive of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/16\">",
"     16",
"    </a>",
"    ]. In contrast, low exercise capacity and less rapid heart rate recovery after exercise are prognostically important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link&amp;anchor=H13#H13\">",
"     \"Stress testing for the diagnosis of coronary heart disease\", section on 'Exercise ECG test'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18\">",
"     'Heart rate recovery after exercise'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Right precordial leads",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise-induced ST segment changes in the right precordial leads can improve the accuracy of the exercise test for diagnosing coronary disease, especially if the right coronary or left circumflex artery is involved. This was illustrated in a study of 245 patients who underwent exercise testing (with recording of the standard 12 leads and the right precordial leads V3 to V5), thallium scintigraphy, and coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/17\">",
"     17",
"    </a>",
"    ]. Compared to the 12 lead ECG alone, the combined use of right precordial leads improved the sensitivity for the detection of any coronary artery disease from 52 to 89 percent with no change in specificity (88 percent).",
"   </p>",
"   <p>",
"    Although intriguing, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines do not recommend the use of right precordial leads until the above findings are confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     ST segment elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise-induced ST segment elevation is uncommon except in leads with a pre-existing Q wave suggesting prior transmural myocardial infarction. ST elevation in such patients is typically due to a wall motion abnormality rather than ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/18\">",
"     18",
"    </a>",
"    ]. An exception occurs in patients with single vessel disease in which ST segment elevation is associated with reciprocal depression in the noninfarcted area; these changes are indicative of residual viability in the infarct-related area [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ST segment elevation in patients with normal resting ECGs is suggestive of transmural ischemia and can occur in two groups of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Variant or Prinzmetal's angina is characterized by episodic chest pain occurring mostly at rest, ST segment elevation during pain, and coronary artery spasm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=see_link\">",
"       \"Variant angina\"",
"      </a>",
"      .) Exercise-induced ST elevation occurs in 10 to 30 percent of these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with severe and often multivessel coronary heart disease may develop transmural ischemia because of a marked decrease in coronary blood flow to a segment of myocardium during exercise. In contrast to ST depression, the leads showing ST elevation in these patients localize the coronary artery responsible for the ischemia. This difference was demonstrated in a study of 452 patients with single vessel coronary disease undergoing exercise testing [",
"      <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/7\">",
"       7",
"      </a>",
"      ]. ST depression occurred most commonly in leads V5 or V6 regardless of which coronary artery was involved. In contrast, anterior ST elevation indicated left anterior descending (LAD) coronary disease in 93 percent of cases, and inferior ST elevation indicated a lesion in or proximal to the posterior descending artery in 86 percent of cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ST segment changes occurring in lead aVR have often been overlooked in the assessment of ischemic heart disease. In a study of 454 patients who underwent exercise stress testing (with or without myocardial perfusion imaging) and then had coronary angiography within six months, 75 patients were found to have severe obstructive coronary artery disease of the left main coronary artery or the ostium of the LAD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/22\">",
"     22",
"    </a>",
"    ]. Following multivariate analysis, ST segment elevation in lead aVR was the strongest predictor of obstructive coronary artery disease involving the left main coronary artery or the ostium of the LAD (sensitivity and specificity of 75 and 81 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     U wave inversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise-induced U wave inversion is uncommon and not well understood from a pathophysiologic perspective (",
"    <a class=\"graphic graphic_figure graphicRef80752 \" href=\"UTD.htm?20/13/20689\">",
"     figure 5",
"    </a>",
"    ). U wave inversion is defined as a discrete negative deflection between the T and P waves relative to the \"isoelectric\" PR segment (",
"    <a class=\"graphic graphic_waveform graphicRef59743 \" href=\"UTD.htm?32/53/33631\">",
"     waveform 2",
"    </a>",
"    ) and is best observed during recovery from exercise as the heart rate slows. The inverted U wave usually becomes upright after several minutes, which helps verify the finding. Resting U wave inversion is a nonspecific finding.",
"   </p>",
"   <p>",
"    U wave inversion was originally described in the early exercise testing literature of the 1940s, but did not reappear for over 30 years, when it was described in 36 of 248 patients (15 percent) who also underwent coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/23\">",
"     23",
"    </a>",
"    ]. Significant coronary disease was found by angiography in all but one of 36 patients, almost all of whom had disease in either the left main or LAD coronary artery.",
"   </p>",
"   <p>",
"    Negative U waves also can be induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography. In a review of 181 patients with suspected coronary heart disease, negative U waves were detected during dobutamine stress echocardiography in 38 (16 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/24\">",
"     24",
"    </a>",
"    ]. The sensitivity and specificity of the negative U wave for significant coronary lesions were 22 and 96 percent, respectively, compared to 49 and 76 percent for ST segment depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ectopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise-induced ventricular ectopy occurs in 7 to 20 percent of patients undergoing exercise ECG testing for known or suspected coronary heart disease. Most studies have noted an association between exercise-induced ventricular arrhythmia and increased mortality risk that may be limited to limited to frequent ventricular ectopy during recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/25\">",
"     25",
"    </a>",
"    ]. Atrial ectopy is also frequent during exercise testing, but does not appear to be an independent predictor of adverse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H7#H7\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Ventricular arrhythmias'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H8#H8\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Atrial arrhythmias'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19\">",
"     'Frequent ventricular ectopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     QT dispersion",
"    </span>",
"    &nbsp;&mdash;&nbsp;QT dispersion, defined as the difference between the maximal and minimal QT interval on a 12 lead ECG, is increased with ischemia. As a result, measurement of QT dispersion may enhance the accuracy of exercise testing, particularly in women. In a report of 64 women, a QT dispersion of greater than 60 msec had significantly greater sensitivity and specificity for coronary heart disease than did ST segment depression of &ge;1 mm (70 versus 55 percent, and 95 versus 63 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/27\">",
"     27",
"    </a>",
"    ]. When both measures were used as criteria for a positive test, specificity increased to 100 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26425?source=see_link\">",
"     \"QT dispersion: Measurement and interpretation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10778?source=see_link\">",
"     \"QT dispersion: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Bundle branch block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left bundle branch block (LBBB) on the baseline ECG masks the ability to identify ischemia during exercise because of the associated ST and T wave abnormalities. Stress testing in patients with LBBB or with a paced ventricular rhythm is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with baseline right bundle branch block (RBBB) and upright ST segments and T waves in leads V5-6 , exercise-induced &ge;0.1 mV horizontal or downsloping ST segment depression detected in these leads is a generally accepted indicator of myocardial ischemia.",
"   </p>",
"   <p>",
"    Another not uncommon problem is the development of bundle branch block (BBB) morphology of the QRS complex during exercise. In a review of 17,277 exercise tests, transient LBBB was noted in 70 (0.4 percent): 40 had a history of coronary heart disease and, among the 43 patients in whom angiography was performed, 35 had significant coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/28\">",
"     28",
"    </a>",
"    ]. The development of LBBB was an independent predictor of death and major cardiac events at four years (adjusted relative risk 2.78 compared to 70 matched controls) (",
"    <a class=\"graphic graphic_figure graphicRef55830 \" href=\"UTD.htm?41/60/42957\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Exercise-induced ventricular premature beats (VPBs) with an LBBB pattern were compared to 2340 matched controls who did not develop a BBB pattern during exercise in a study of 198 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/29\">",
"     29",
"    </a>",
"    ]. At a mean follow-up of 24 years, the patients with LBBB had a similar mortality as those without BBB. However, the authors noted that an exercise-induced LBBB pattern of VPBs can occur in patients at risk of death, such as those with arrhythmogenic right ventricular cardiomyopathy or prior septal myocardial infarction.",
"   </p>",
"   <p>",
"    The same study included 250 patients with exercise-induced VPBs with a RBBB pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/29\">",
"     29",
"    </a>",
"    ]. These patients had a significantly increased mortality compared to those who did not develop a BBB pattern (6.4 versus 2.5 percent).",
"   </p>",
"   <p>",
"    A separate issue is the development of rate related bundle branch block. This often represents underlying conduction system disease, but is often misdiagnosed as ventricular tachycardia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Heart rate increase",
"    </span>",
"    &nbsp;&mdash;&nbsp;An impaired heart rate response to exercise, known as chronotropic incompetence, is generally defined as failure to achieve 85 percent of the age-predicted maximum heart rate. Chronotropic incompetence, which occurred in 21 percent of consecutive patients referred for symptom-limited exercise testing in a series of patients who were not taking beta blockers, may be predictive of coronary heart disease risk and all-cause mortality (",
"    <a class=\"graphic graphic_figure graphicRef70339 \" href=\"UTD.htm?15/3/15421\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H4#H4\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Heart rate response to exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although routine screening for coronary heart disease is not recommended, a study in which this was performed with exercise ECG testing found that individuals in the lowest quintile of heart rate increase (less than 89",
"    <span class=\"nowrap\">",
"     beats/min)",
"    </span>",
"    had a significant, although quantitatively small, increase in sudden death but not non-sudden cardiac death at long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients with chronotropic incompetence were excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link&amp;anchor=H10#H10\">",
"     \"Screening for coronary heart disease\", section on 'High-risk patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ECG ABNORMALITIES DURING RECOVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the changes that are induced by ischemia during exercise, certain changes that occur during recovery also have diagnostic and prognostic significance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     ST segment depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of patients (approximately 8 percent in two studies) develop ST segment depression during recovery rather than during exercise; this change is a predictor of a greater likelihood of coronary heart disease and may have a prognostic significance similar to similar changes occurring during exercise, even in apparently healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In a review of 328 men who underwent a symptom-limited treadmill test and coronary angiography, abnormal ST segment responses were noted in 168 and occurred only during recovery in 26 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/32\">",
"     32",
"    </a>",
"    ]. The positive predictive value for significant angiographic coronary artery disease was similar when ST depression occurred during recovery or exercise (84 versus 87 percent). Furthermore, inclusion of ST depression during recovery significantly increased the sensitivity of the exercise test (from 50 to 59 percent) without change in predictive value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Heart rate recovery after exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;The progressive rise in heart rate with exercise is mediated by an increase in sympathetic activity and a decline in parasympathetic activity. These changes are reversed and the heart rate slows during recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/34\">",
"     34",
"    </a>",
"    ]. A slower rate of heart rate recovery is associated with impaired reactivation of parasympathetic tone and has been shown to be a marker of adverse prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H5#H5\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Heart rate recovery after exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Frequent ventricular ectopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an association between exercise-induced ventricular arrhythmia and increased mortality risk. In a review of almost 30,000 patients referred to symptom-limited exercise testing who did not have a history of heart failure, arrhythmia, or valve disease, frequent ventricular ectopy occurred only during exercise in 3 percent, only during recovery in 2 percent, and in both time periods in 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/25\">",
"     25",
"    </a>",
"    ]. At a mean 5.3 year follow-up, only frequent ventricular ectopy occurring during recovery was associated with an increased risk of mortality after adjusting for confounding variables. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H7#H7\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Ventricular arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RISK SCORES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of general adverse predictors have been identified during exercise testing. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor exercise capacity (&lt;5 METs)",
"     </li>",
"     <li>",
"      Abnormally low peak systolic blood pressure (&lt;130 mmHg) or a fall in systolic blood pressure during exercise",
"     </li>",
"     <li>",
"      Exercise-induced angina",
"     </li>",
"     <li>",
"      &ge;2 mm of ischemic ST depression at a low workload (stage 2 or less or &le;130",
"      <span class=\"nowrap\">",
"       beats/min)",
"      </span>",
"     </li>",
"     <li>",
"      Early onset (stage 1) or prolonged duration (&gt;5 min) of ST depression",
"     </li>",
"     <li>",
"      Multiple leads (&gt;5) with ST depression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most popular validated treadmill score comes from Duke University and is based upon data from 2758 consecutive patients with a median age of 49 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/35\">",
"     35",
"    </a>",
"    ]. The Duke treadmill score (DTS) uses three exercise parameters to calculate risk:",
"   </p>",
"   <p>",
"    &nbsp;DTS = Exercise time &ndash; (5 x maximum ST segment deviation in mm) &ndash; (4 x exercise angina score)",
"   </p>",
"   <p>",
"    Exercise time is measured in minutes completed on the Bruce protocol. Exercise angina is rated as: none (0), nonlimiting (1), or exercise limiting (2). Patients are classified as low, moderate, or high risk according to the score:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk &mdash; score &ge;+5",
"     </li>",
"     <li>",
"      Moderate risk &mdash; score from -10 to +4",
"     </li>",
"     <li>",
"      High risk &mdash; score &le;-11",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The scores roughly correlated with both the severity of coronary heart disease and prognosis in men (",
"    <a class=\"graphic graphic_figure graphicRef59562 \" href=\"UTD.htm?34/10/34989\">",
"     figure 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/35\">",
"     35",
"    </a>",
"    ] but may be less effective for risk stratification in women (",
"    <a class=\"graphic graphic_figure graphicRef79590 \" href=\"UTD.htm?14/55/15230\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11017/abstract/36\">",
"     36",
"    </a>",
"    ]. The utility and limitations of the Duke treadmill score are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H11#H11\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Duke treadmill score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       \"Patient information: ECG and stress test (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7224190\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    Exercise electrocardiographic (ECG) testing indirectly detects myocardial ischemia, which results from a transient imbalance between myocardial oxygen delivery (coronary blood flow) and myocardial oxygen demand (myocardial work). (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Certain baseline ECG abnormalities preclude accurate interpretation of post-exercise ECG changes. These baseline abnormalities include (see",
"    <a class=\"local\" href=\"#H3\">",
"     'ECG abnormalities during exercise'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preexcitation (Wolff-Parkinson-White) syndrome",
"     </li>",
"     <li>",
"      Complete left bundle branch block (LBBB)",
"     </li>",
"     <li>",
"      Greater than 1 mm ST segment depression at rest",
"     </li>",
"     <li>",
"      Paced ventricular rhythm",
"     </li>",
"     <li>",
"      Repolarization abnormalities in a patient taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following ECG changes may be seen during exercise (",
"    <a class=\"graphic graphic_figure graphicRef80752 \" href=\"UTD.htm?20/13/20689\">",
"     figure 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depression of the J point (end of the QRS complex and beginning of the ST segment) is normally seen with increasing heart rates during exercise and is not felt to be related to myocardial ischemia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'ST segment depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Upsloping ST depression appears first during exercise and is less specific for ischemia than horizontal ST depression. In contrast, horizontal or downsloping ST depression of &ge;1 mm (",
"      <a class=\"graphic graphic_waveform graphicRef56740 \" href=\"UTD.htm?19/48/20225\">",
"       waveform 1",
"      </a>",
"      ), often with associated T wave inversion, may be seen during exercise but is most often seen during recovery from exercise and is more specific for ischemia. When the criteria for a positive exercise ECG test are defined as &ge;1 mm horizontal or downsloping ST segment depression, the mean sensitivity and specificity for coronary heart disease is approximately 60 and 90 percent, respectively. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'ST segment depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ST segment elevation during exercise in patients with a normal resting ECG is suggestive of transmural ischemia. This finding during exercise ECG testing can be seen in two settings: (See",
"      <a class=\"local\" href=\"#H10\">",
"       'ST segment elevation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with variant or Prinzmetal's angina resulting from coronary artery spasm.",
"     </li>",
"     <li>",
"      Patients with severe (often multivessel) coronary heart disease who develop transmural ischemia because of a marked decrease in coronary blood flow to a segment of myocardium during exercise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ST segment elevation in lead aVR during exercise stress testing is suggestive of significant obstructive coronary artery disease involving the left main coronary artery or the ostium of the left anterior descending artery. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'ST segment elevation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exercise-induced ventricular ectopy occurs in approximately 7 to 20 percent of patients undergoing exercise ECG testing. Most studies have noted an association between exercise-induced ventricular arrhythmia and increased mortality risk, most notably in patients with frequent ventricular ectopy during recovery. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Ectopy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Frequent ventricular ectopy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H7#H7\">",
"       \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Ventricular arrhythmias'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast to patients with a chronic LBBB (whose ECG with exercise is uninterpretable), diagnostic information can be obtained from patients with a baseline right bundle branch block (RBBB) whose ST segments and T waves in leads V5-6 (or other leads with wide terminal S waves) are upright. Exercise-induced &ge;0.1 mV horizontal or downsloping ST segment depression detected in these leads is a generally accepted indicator of myocardial ischemia. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Bundle branch block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An impaired heart rate response to exercise, known as chronotropic incompetence, is generally defined as failure to achieve 85 percent of the age-predicted maximum heart rate. Chronotropic incompetence may be predictive of coronary heart disease risk and all-cause mortality. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Heart rate increase'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H4#H4\">",
"       \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Heart rate response to exercise'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Duke treadmill score stratifies patients into low, intermediate, or high risk based on data derived from exercise ECG testing, including ST segment depression, exercise time, and chest pain. The Duke treadmill score roughly correlates with both the severity of coronary heart disease and prognosis. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Risk scores'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/1\">",
"      Hauser AM, Gangadharan V, Ramos RG, et al. Sequence of mechanical, electrocardiographic and clinical effects of repeated coronary artery occlusion in human beings: echocardiographic observations during coronary angioplasty. J Am Coll Cardiol 1985; 5:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/2\">",
"      Wohlgelernter D, Cleman M, Highman HA, et al. Regional myocardial dysfunction during coronary angioplasty: evaluation by two-dimensional echocardiography and 12 lead electrocardiography. J Am Coll Cardiol 1986; 7:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/3\">",
"      Vincent GM, Abildskov JA, Burgess MJ. Mechanisms of ischemic ST-segment displacement. Evaluation by direct current recordings. Circulation 1977; 56:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/4\">",
"      Holland RP, Brooks H. Precordial and epicardial surface potentials during Myocardial ischemia in the pig. A theoretical and experimental analysis of the TQ and ST segments. Circ Res 1975; 37:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/5\">",
"      Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. Circulation 1989; 80:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/6\">",
"      Miranda CP, Liu J, Kadar A, et al. Usefulness of exercise-induced ST-segment depression in the inferior leads during exercise testing as a marker for coronary artery disease. Am J Cardiol 1992; 69:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/7\">",
"      Mark DB, Hlatky MA, Lee KL, et al. Localizing coronary artery obstructions with the exercise treadmill test. Ann Intern Med 1987; 106:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/8\">",
"      Tavel ME, Shaar C. Relation between the electrocardiographic stress test and degree and location of myocardial ischemia. Am J Cardiol 1999; 84:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/9\">",
"      Rijneke RD, Ascoop CA, Talmon JL. Clinical significance of upsloping ST segments in exercise electrocardiography. Circulation 1980; 61:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/10\">",
"      Stuart RJ, Ellestad MH. Upsloping S-T segments in exercise stress testing. Six year follow-up study of 438 patients and correlation with 248 angiograms. Am J Cardiol 1976; 37:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/11\">",
"      Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/12\">",
"      Rywik TM, O'Connor FC, Gittings NS, et al. Role of nondiagnostic exercise-induced ST-segment abnormalities in predicting future coronary events in asymptomatic volunteers. Circulation 2002; 106:2787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/13\">",
"      Fearon WF, Lee DP, Froelicher VF. The effect of resting ST segment depression on the diagnostic characteristics of the exercise treadmill test. J Am Coll Cardiol 2000; 35:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/14\">",
"      Kalaria VG, Dwyer EM. Ability of the exercise electrocardiogram test to detect ischemia in stable coronary artery disease patients with ST-segment depression on the resting electrocardiogram. Am Heart J 1998; 135:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/15\">",
"      Kwok JM, Miller TD, Christian TF, et al. Prognostic value of a treadmill exercise score in symptomatic patients with nonspecific ST-T abnormalities on resting ECG. JAMA 1999; 282:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/16\">",
"      Mora S, Redberg RF, Cui Y, et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. JAMA 2003; 290:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/17\">",
"      Michaelides AP, Psomadaki ZD, Dilaveris PE, et al. Improved detection of coronary artery disease by exercise electrocardiography with the use of right precordial leads. N Engl J Med 1999; 340:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/18\">",
"      Stiles GL, Rosati RA, Wallace AG. Clinical relevance of exercise-induced S-T segment elevation. Am J Cardiol 1980; 46:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/19\">",
"      Nakano A, Lee JD, Shimizu H, et al. Reciprocal ST-segment depression associated with exercise-induced ST-segment elevation indicates residual viability after myocardial infarction. J Am Coll Cardiol 1999; 33:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/20\">",
"      Lahiri A, Subramanian B, Millar-Craig M, et al. Exercise-induced S-T segment elevation in variant angina. Am J Cardiol 1980; 45:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/21\">",
"      Matsuda Y, Ozaki M, Ogawa H, et al. Coronary arteriography and left ventriculography during spontaneous and exercise-induced ST segment elevation in patients with variant angina. Am Heart J 1983; 106:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/22\">",
"      Uthamalingam S, Zheng H, Leavitt M, et al. Exercise-induced ST-segment elevation in ECG lead aVR is a useful indicator of significant left main or ostial LAD coronary artery stenosis. JACC Cardiovasc Imaging 2011; 4:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/23\">",
"      Gerson MC, Phillips JF, Morris SN, McHenry PL. Exercise-induced U-wave inversion as a marker of stenosis of the left anterior descending coronary artery. Circulation 1979; 60:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/24\">",
"      Miura Y, Takeuchi M, Sonoda S, et al. Implication of the negative U wave during dobutamine stress echocardiography. J Electrocardiol 1997; 30:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/25\">",
"      Frolkis JP, Pothier CE, Blackstone EH, Lauer MS. Frequent ventricular ectopy after exercise as a predictor of death. N Engl J Med 2003; 348:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/26\">",
"      Bunch TJ, Chandrasekaran K, Gersh BJ, et al. The prognostic significance of exercise-induced atrial arrhythmias. J Am Coll Cardiol 2004; 43:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/27\">",
"      Stoletniy LN, Pai RG. Value of QT dispersion in the interpretation of exercise stress test in women. Circulation 1997; 96:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/28\">",
"      Grady TA, Chiu AC, Snader CE, et al. Prognostic significance of exercise-induced left bundle-branch block. JAMA 1998; 279:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/29\">",
"      Eckart RE, Field ME, Hruczkowski TW, et al. Association of electrocardiographic morphology of exercise-induced ventricular arrhythmia with mortality. Ann Intern Med 2008; 149:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/30\">",
"      Lauer MS, Mehta R, Pashkow FJ, et al. Association of chronotropic incompetence with echocardiographic ischemia and prognosis. J Am Coll Cardiol 1998; 32:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/31\">",
"      Jouven X, Empana JP, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/32\">",
"      Lachterman B, Lehmann KG, Abrahamson D, Froelicher VF. \"Recovery only\" ST-segment depression and the predictive accuracy of the exercise test. Ann Intern Med 1990; 112:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/33\">",
"      Rywik TM, Zink RC, Gittings NS, et al. Independent prognostic significance of ischemic ST-segment response limited to recovery from treadmill exercise in asymptomatic subjects. Circulation 1998; 97:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/34\">",
"      Imai K, Sato H, Hori M, et al. Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure. J Am Coll Cardiol 1994; 24:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/35\">",
"      Shaw LJ, Peterson ED, Shaw LK, et al. Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups. Circulation 1998; 98:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11017/abstract/36\">",
"      Alexander KP, Shaw LJ, Shaw LK, et al. Value of exercise treadmill testing in women. J Am Coll Cardiol 1998; 32:1657.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1500 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-49D3304717-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_48_11017=[""].join("\n");
var outline_f10_48_11017=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7224190\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ELECTROPHYSIOLOGY OF MYOCARDIAL ISCHEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ECG ABNORMALITIES DURING EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ST segment depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Flat or downsloping ST depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Upsloping ST depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Resting ST depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Right precordial leads",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ST segment elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      U wave inversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ectopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      QT dispersion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Heart rate increase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ECG ABNORMALITIES DURING RECOVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ST segment depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Heart rate recovery after exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Frequent ventricular ectopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RISK SCORES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7224190\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1500\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1500|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/60/33741\" title=\"figure 1\">",
"      Time course cardiac ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/24/27023\" title=\"figure 2\">",
"      Action potential and ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/45/14035\" title=\"figure 3\">",
"      Subendocardial injury current with exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/14/2274\" title=\"figure 4\">",
"      Subepicardial transmural injury current",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/13/20689\" title=\"figure 5\">",
"      ECG changes with exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/60/42957\" title=\"figure 6\">",
"      Exercise-induced LBBB and outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/3/15421\" title=\"figure 7\">",
"      ETT maximal HR outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/10/34989\" title=\"figure 8\">",
"      Duke Treadmill Score and survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/55/15230\" title=\"figure 9\">",
"      Duke Treadmill Score and prognosis by gender",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1500|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/51/13118\" title=\"table 1\">",
"      Exercise testing protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/28/14796\" title=\"table 2\">",
"      Exercise test endpoints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/19/2365\" title=\"table 3\">",
"      ACC AHA indication stopping ETT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/23/3451\" title=\"table 4\">",
"      ECG exercise and ST depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1500|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?19/48/20225\" title=\"waveform 1\">",
"      Exercise test ST seg changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?32/53/33631\" title=\"waveform 2\">",
"      U wave inversion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/50/15144?source=related_link\">",
"      Pathophysiology and clinical presentation of ischemic chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10778?source=related_link\">",
"      QT dispersion: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26425?source=related_link\">",
"      QT dispersion: Measurement and interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=related_link\">",
"      Stress testing in patients with left bundle branch block or a paced ventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=related_link\">",
"      Variant angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_48_11018="General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)";
var content_f10_48_11018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/48/11018/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11018/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/48/11018/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11018/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/48/11018/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/48/11018/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/48/11018/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of water balance and sodium balance are common, but the pathophysiology is frequently misunderstood. As an example, the plasma sodium concentration is regulated by changes in water intake and excretion, not by changes in sodium balance. As will be described in the following sections, hyponatremia is primarily due to the intake of water that cannot be excreted, hypernatremia is primarily due to the loss of water that has not been replaced, hypovolemia represents the loss of sodium and water, and edema is primarily due to sodium and water retention. Understanding these basic principles is essential for appropriate diagnosis and treatment.",
"   </p>",
"   <p>",
"    The general principles and disorders of water balance and sodium balance will be reviewed here. The causes and evaluation of hyponatremia, hypernatremia, hypovolemia, and edema are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link\">",
"     \"Etiology and evaluation of hypernatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=see_link\">",
"     \"Clinical manifestations and diagnosis of edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following terms are commonly used when discussing disorders of water and sodium balance. Understanding what these terms represent is essential for appropriate diagnosis and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37261016\">",
"    <span class=\"h2\">",
"     Total body water",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total body water (TBW) as a percentage of",
"    <strong>",
"     lean",
"    </strong>",
"    body weight varies with age. Approximate normal values are 80 percent in premature infants, 70 to 75 percent in term infants, 65 to 70 percent in toddlers, and 60 percent after puberty (",
"    <a class=\"graphic graphic_figure graphicRef56512 \" href=\"UTD.htm?32/46/33518\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11018/abstract/1\">",
"     1",
"    </a>",
"    ]. These values vary with the amount of fat since fat has a much lower water content than muscle. Thus, the TBW as a percentage of total body weight is lower in individuals with more fat. As examples, the TBW as a percentage of total body weight is lower in young adult females than in young adult males (50 versus 60 percent) and becomes progressively lower with increasing obesity or with loss of muscle mass.",
"   </p>",
"   <p>",
"    The TBW has two main compartments: the",
"    <strong>",
"     extracellular fluid",
"    </strong>",
"    and the",
"    <strong>",
"     intracellular fluid",
"    </strong>",
"    , which are separated by the cell membrane. The relative size of the two main compartments varies with age. The extracellular fluid component is increased in infants and young children compared with older patients, which also contributes to the younger patients&rsquo; greater TBW percentage of lean body weight (",
"    <a class=\"graphic graphic_figure graphicRef56512 \" href=\"UTD.htm?32/46/33518\">",
"     figure 1",
"    </a>",
"    ). The cell membranes are freely permeable to water but not electrolytes and therefore help to maintain the different solute composition of the two compartments: sodium salts in the extracellular fluid, with chloride and bicarbonate being the major anions; and potassium salts in the intracellular fluid, with large macromolecular organic phosphates being the main anions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Extracellular fluid volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extracellular fluid component varies with age and is increased in infants and young children (",
"    <a class=\"graphic graphic_figure graphicRef56512 \" href=\"UTD.htm?32/46/33518\">",
"     figure 1",
"    </a>",
"    ). In normal adults, the extracellular fluid (ECF) volume constitutes approximately 33 to 40 percent of the TBW [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11018/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] and is determined by the absolute amounts of sodium and water that are present in the ECF. For the remainder of this discussion, we will use 33 percent (one-third) with the remaining 67 percent (two-thirds) of the TBW being in the cells. (See",
"    <a class=\"local\" href=\"#H24579285\">",
"     'Intracellular fluid volume'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The ECF volume is regulated by alterations in urinary sodium excretion that are primarily mediated by variations in the activity of the renin-angiotensin-aldosterone and sympathetic nervous systems, which promote sodium retention, and the secretion of natriuretic peptides, which promote sodium excretion. (See",
"    <a class=\"local\" href=\"#H96014906\">",
"     'Regulation of effective arterial blood volume'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37261267\">",
"    <span class=\"h4\">",
"     Effective arterial blood volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hormonal changes that regulate the ECF volume are mediated by sensors in the renal afferent glomerular arterioles (for renin), carotid sinus (for sympathetic activity), and atria and ventricles (for natriuretic peptides) that respond to changes in pressure, not volume. In most settings, pressure and volume change in parallel with changes in sodium intake or with gastrointestinal or renal sodium losses due, for example, to diarrhea or diuretic therapy.",
"   </p>",
"   <p>",
"    Loss of ECF volume can lead to a reduction in tissue perfusion. However, the ECF volume and tissue perfusion do not always change in the same direction. Two common examples are heart failure with edema and cirrhosis with ascites. In both disorders, the ECF volume is",
"    <strong>",
"     increased",
"    </strong>",
"    , but tissue perfusion is",
"    <strong>",
"     reduced",
"    </strong>",
"    due to a low cardiac output in most cases of heart failure and to vasodilation in cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathophysiology and etiology of edema in adults\", section on 'Heart failure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=see_link\">",
"     \"Pathogenesis of ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reduced effective arterial blood volume or reduced effective circulating volume are terms that have been used to describe the discrepancy between hypoperfusion and the increase in extracellular volume in heart failure and cirrhosis. In both disorders, decreased tissue perfusion activates sodium-retaining hormones, which increase the extracellular volume but, due to the underlying disease, do not normalize tissue perfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24579285\">",
"    <span class=\"h3\">",
"     Intracellular fluid volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal adults, the intracellular fluid volume constitutes approximately 60 to 67 percent of the TBW [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11018/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Potassium salts are the main intracellular solutes, and the intracellular fluid volume is larger than the ECF volume because there are more potassium salts in the cells than sodium salts in the ECF. Changes in the intracellular fluid volume primarily occur when there are changes in plasma tonicity, resulting in water movement into or out of the cells. As described below, the intracellular and brain volumes usually increase with hyponatremia and decrease with hypernatremia (see",
"    <a class=\"local\" href=\"#H37261099\">",
"     'Plasma tonicity'",
"    </a>",
"    below). Water movement into or out of cells and possible neurologic symptoms are most pronounced with acute changes in the plasma sodium and often attenuate over time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H4#H4\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Osmolytes and cerebral adaptation to hyponatremia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H11#H11\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Cerebral adaptation to hypernatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37261092\">",
"    <span class=\"h2\">",
"     Plasma osmolality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma osmolality (Posm) is determined by the",
"    <strong>",
"     ratio",
"    </strong>",
"    of plasma solutes and plasma water. Most of the plasma solutes are sodium salts with lesser contributions from other ions (eg, potassium, calcium), glucose, and urea. The normal Posm is 275 to 290",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"   </p>",
"   <p>",
"    The plasma osmolality can be estimated from the following equation (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?27/45/28370?source=see_link\">",
"     calculator 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    Posm &nbsp;= &nbsp;2 x [Na] &nbsp;+ &nbsp;",
"    <span class=\"nowrap\">",
"     [glucose]/18",
"    </span>",
"    &nbsp;+ &nbsp;blood urea",
"    <span class=\"nowrap\">",
"     nitrogen/2.8",
"    </span>",
"   </p>",
"   <p>",
"    The multiple of 2 accounts for the anions accompanying sodium, and the divisors of 18 and 2.8 for glucose and the blood urea nitrogen convert the values in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    If, as in many countries outside the United States, the glucose and urea concentrations are reported in",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    the equation becomes (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?20/19/20786?source=see_link\">",
"     calculator 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    Posm &nbsp;= &nbsp;2 x [Na] &nbsp;+ &nbsp;[glucose] &nbsp;+ &nbsp;[urea]",
"   </p>",
"   <p>",
"    The contributions of glucose and urea are small when their concentrations are within the normal range; they become significant when marked elevations develop as with uncontrolled diabetes mellitus or reduced renal function, respectively. &nbsp;",
"   </p>",
"   <p>",
"    The plasma and ECF osmolality are the",
"    <strong>",
"     same",
"    </strong>",
"    as the intracellular osmolality since most cell membranes are freely permeable to water.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37261099\">",
"    <span class=\"h2\">",
"     Plasma tonicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma tonicity, also called the",
"    <strong>",
"     effective",
"    </strong>",
"    plasma osmolality, is the parameter sensed by osmoreceptors and determines the transcellular distribution of water. Water can freely cross almost all cell membranes and moves from an area of lower tonicity (higher water content) to an area of higher tonicity (lower water content).",
"   </p>",
"   <p>",
"    The main difference between plasma tonicity and plasma osmolality is that plasma tonicity reflects the concentration of solutes that do not easily cross cell membranes (mostly sodium salts) and therefore affect the distribution of water between the cells and the ECF. In contrast, the plasma osmolality also includes the osmotic contribution of urea, which is considered an \"ineffective\" osmole since it can equilibrate across the cell membrane and therefore has little effect on water movement across the cell membrane. Ethanol is another osmole that rapidly enters cells and therefore has no tonicity.",
"   </p>",
"   <p>",
"    The formulas used to estimate plasma tonicity are similar to those for the plasma osmolality with the one exception that the contribution of urea is not included:",
"   </p>",
"   <p>",
"    Plasma tonicity &nbsp;= &nbsp;2 x [Na] &nbsp;+ &nbsp;",
"    <span class=\"nowrap\">",
"     [glucose]/18",
"    </span>",
"    (if glucose is measured in",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"   </p>",
"   <p>",
"    Plasma tonicity &nbsp;= &nbsp;2 x [Na] &nbsp;+ &nbsp;[glucose] (if glucose is measured in",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"   </p>",
"   <p>",
"    The following examples illustrate the clinical importance of plasma tonicity and the difference between tonicity and osmolality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyponatremia is, in most cases, accompanied by a fall in plasma tonicity, which results in osmotic water movement from the ECF",
"      <strong>",
"       into",
"      </strong>",
"      the cells, including brain cells, and can contribute to the neurologic symptoms of hyponatremia. In this setting, both the plasma tonicity and plasma osmolality are reduced. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H2#H2\">",
"       \"Manifestations of hyponatremia and hypernatremia\", section on 'Hyponatremia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypernatremia is accompanied by an increase in plasma tonicity, which results in osmotic water movement",
"      <strong>",
"       out of",
"      </strong>",
"      the cells, including brain cells, and can contribute to the neurologic symptoms of hypernatremia. In this setting, both the plasma osmolality and plasma tonicity are increased. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H9#H9\">",
"       \"Manifestations of hyponatremia and hypernatremia\", section on 'Hypernatremia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast, urea accumulation in renal failure is associated with urea equilibration across the cell membrane. The plasma osmolality is increased by the excess urea, but the plasma tonicity is",
"      <strong>",
"       unchanged",
"      </strong>",
"      because urea is an",
"      <strong>",
"       ineffective",
"      </strong>",
"      osmole. As a result, there is little transcellular water movement. If, however, a patient with renal failure develops hyponatremia or hypernatremia, the changes in plasma tonicity will result in movement into and out of cells, respectively, similar to that seen in patients without renal failure. The plasma osmolality may still be elevated in patients with hyponatremia, but the plasma tonicity will be reduced.",
"      <br/>",
"      <br/>",
"      Urea equilibration across the cell membranes occurs more slowly than water equilibration. Thus, urea can transiently act as an",
"      <strong>",
"       effective",
"      </strong>",
"      osmole when its plasma concentration changes rapidly. The most common example of this phenomenon is the rapid fall in plasma urea concentration produced by hemodialysis in a uremic patient. In this setting, the removal of extracellular urea occurs more quickly than urea can equilibrate across the cell membrane. Thus, the plasma osmolality falls much more rapidly than the intracellular osmolality, which promotes osmotic water movement into cells. In the brain, the water shift can result in cerebral edema and acute neurologic dysfunction, changes that partially explain the dialysis disequilibrium syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=see_link&amp;anchor=H3#H3\">",
"       \"Dialysis disequilibrium syndrome\", section on 'Reverse osmotic shift'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165025474\">",
"    <span class=\"h2\">",
"     Dehydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dehydration is defined as a reduction in TBW below the normal level without a proportional reduction in sodium and potassium, resulting in a rise in the plasma sodium concentration. (See",
"    <a class=\"local\" href=\"#H325761326\">",
"     'Determinants of the plasma sodium concentration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With primary loss of free water (as with unreplaced insensible losses or water loss in diabetes insipidus), the major biochemical manifestation is hypernatremia. Because water equilibrates across the cell membrane, about two-thirds of the water losses come from the cells and one-third from the ECF. Thus, 3 L of free water would have to be lost to produce the same reduction in ECF volume as the loss of 1 L of isotonic saline. Thus, signs of hypovolemia are",
"    <strong>",
"     not",
"    </strong>",
"    present unless there is a marked degree of free water loss. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Extracellular fluid volume'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H24579285\">",
"     'Intracellular fluid volume'",
"    </a>",
"    above.)",
"    <br/>",
"   </p>",
"   <p>",
"    As described in the next section, hypernatremia does not usually occur in patients who have an intact thirst mechanism and access to water since stimulation of thirst can replace most of the water deficit. (See",
"    <a class=\"local\" href=\"#H96014898\">",
"     'Regulation of plasma tonicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96014928\">",
"    <span class=\"h1\">",
"     REGULATION OF WATER AND SODIUM BALANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kidney regulates water and sodium balance independently since water can be taken in without salt and salt can be taken in without water (eg, pretzels or potato chips). Regulation of plasma tonicity and of the effective arterial blood volume involve different hormones, although there are some areas of overlap, such as the hypovolemic stimulus to the release of antidiuretic hormone (ADH). (See",
"    <a class=\"local\" href=\"#H96014936\">",
"     'Combined regulation of plasma tonicity and effective arterial blood volume'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96014898\">",
"    <span class=\"h2\">",
"     Regulation of plasma tonicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, it is the plasma tonicity (also called effective plasma osmolality) that is of primary importance in osmoregulation. Plasma osmolality measurement may include a high concentration of solutes that do",
"    <strong>",
"     not",
"    </strong>",
"    affect tonicity (eg, urea in renal failure or ethanol in intoxicated patients). These \"ineffective\" osmoles do not affect fluid movement into or out of cells unless there is a change in concentration that is more rapid than the time required for equilibration with the cells, as can occur with hemodialysis in patients with renal failure. (See",
"    <a class=\"local\" href=\"#H37261099\">",
"     'Plasma tonicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Changes in plasma tonicity are sensed by osmoreceptors in the hypothalamus. These receptors affect both water intake and water excretion by influencing thirst and the release of ADH, respectively (",
"    <a class=\"graphic graphic_figure graphicRef65195 \" href=\"UTD.htm?14/61/15325\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51153 \" href=\"UTD.htm?22/41/23195\">",
"     table 1",
"    </a>",
"    ). ADH causes water retention by enhancing the permeability of the collecting tubules to water. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=see_link\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, osmoregulation is achieved by alterations in",
"    <strong>",
"     water balance",
"    </strong>",
"    . Suppression of ADH release is the primary protective mechanism against water retention and the development of hyponatremia, while thirst is the primary protective mechanism against water loss and the development of hypernatremia. This regulatory system is so efficient that, in normal individuals, there is usually no more than a 1 or 2 percent variability in plasma osmolality despite wide fluctuations in water and solute intake.",
"   </p>",
"   <p>",
"    Persistent water retention resulting in hypoosmolality and hyponatremia occurs, with rare exceptions, only in patients with an impairment in renal water excretion due either to an inability to suppress the release of ADH (most often due to reduced effective arterial blood volume, as seen in true hypovolemia, heart failure, cirrhosis, or the syndrome of inappropriate ADH secretion) (SIADH), or to advanced renal failure in which water retention is largely independent of ADH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, correction of a water deficit (caused, for example, by sweating on a hot day) requires the intake and retention of exogenous water. This is achieved by increases in thirst and ADH release, which are induced by the elevation in plasma tonicity (",
"    <a class=\"graphic graphic_figure graphicRef71817 \" href=\"UTD.htm?42/31/43518\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In contrast to the response to hypotonicity, in which renal water excretion is of primary importance,",
"    <strong>",
"     thirst",
"    </strong>",
"    is the major defense against hypertonicity and hypernatremia. Hypernatremia generally will",
"    <strong>",
"     not",
"    </strong>",
"    occur in a patient with a normal thirst mechanism and access to water. It is primarily seen in patients with impaired mental status (elderly or critically ill) who do not experience thirst or in infants who can experience thirst but require others to provide fluid intake. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link&amp;anchor=H2#H2\">",
"     \"Etiology and evaluation of hypernatremia\", section on 'The importance of thirst'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96014906\">",
"    <span class=\"h2\">",
"     Regulation of effective arterial blood volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in body sodium content lead to changes in extracellular fluid (ECF) volume and effective arterial blood volume, which is defined above. (See",
"    <a class=\"local\" href=\"#H37261267\">",
"     'Effective arterial blood volume'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Changes in effective arterial blood volume are sensed by three major pressure receptors which activate specific systems that regulate both systemic vascular resistance and sodium excretion (",
"    <a class=\"graphic graphic_table graphicRef51153 \" href=\"UTD.htm?22/41/23195\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Receptors in specialized cells in the afferent glomerular arteriole (called juxtaglomerular cells) sense the perfusion pressure in the kidney and are an important determinant of the activity of the renin-angiotensin-aldosterone system, which increases with renal hypoperfusion (",
"      <a class=\"graphic graphic_figure graphicRef69949 \" href=\"UTD.htm?31/9/31889\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef65116 \" href=\"UTD.htm?14/19/14654\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Receptors in the carotid sinus and aorta regulate the activity of the sympathetic nervous system [",
"      <a class=\"abstract\" href=\"UTD.htm?10/48/11018/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Increased sympathetic activity also increases renin release (",
"      <a class=\"graphic graphic_figure graphicRef65116 \" href=\"UTD.htm?14/19/14654\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cardiac receptors regulate the release of atrial natriuretic peptide (mostly from the atria) and brain natriuretic peptide (mostly from the ventricles).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Angiotensin II and norepinephrine are vasoconstrictors; aldosterone, angiotensin II, and norepinephrine also promote sodium reabsorption. The natriuretic peptides are vasodilators that increase sodium excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In response to volume expansion due to a high salt intake, natriuretic peptide secretion is increased while the renin-angiotensin-aldosterone system is suppressed (",
"    <a class=\"graphic graphic_figure graphicRef53243 \" href=\"UTD.htm?0/58/941\">",
"     figure 6",
"    </a>",
"    ), changes that promote urinary excretion of the larger sodium load.",
"   </p>",
"   <p>",
"    In contrast, volume contraction will have the opposite effect. In addition, a reduced effective arterial blood volume (even in a hypervolemic patient) activates the renin-angiotensin-aldosterone and sympathetic nervous systems. These hormonal changes result in both sodium retention and vasoconstriction, thereby maintaining the ECF volume and systemic blood pressure. However, when the renin-angiotensin-aldosterone system is markedly activated in these conditions, vasodilatory and natriuretic peptides as well as other hormones (such as prostaglandins) are often also increased. These counterregulatory factors act to moderate the degree of vasoconstriction and salt retention [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11018/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    The importance of these moderating factors is evident, for example, when prostaglandin inhibitors (such as nonsteroidal antiinflammatory drugs) are given to a patient with cirrhosis or severe heart failure. The inhibition of vasodilatory prostaglandins leads to marked salt retention and acute kidney dysfunction. These adverse effects are due to the development of unopposed vasoconstriction and salt retention.",
"   </p>",
"   <p>",
"    The diagnosis of reduced effective arterial blood volume is usually made from the history, physical examination (postural hypotension or poor skin turgor with true volume depletion, edema in heart failure, ascites in cirrhosis), and by demonstrating renal sodium retention as evidenced by a urine sodium concentration below 25",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    unless there is renal sodium wasting (most often due to diuretic therapy or underlying renal disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165025668\">",
"    <span class=\"h3\">",
"     Later role of ADH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the primary role of volume regulating hormones, a substantial reduction in the effective arterial blood volume can also lead to the release of ADH (",
"    <a class=\"graphic graphic_figure graphicRef58012 \" href=\"UTD.htm?2/33/2589\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11018/abstract/8\">",
"     8",
"    </a>",
"    ]. The ensuing retention of water will partially restore the ECF volume but, as noted above, most (about two-thirds) of the retained water will move osmotically into the cells. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Extracellular fluid volume'",
"    </a>",
"    above.) Water retention will also lower the plasma sodium concentration.",
"   </p>",
"   <p>",
"    In patients with heart failure and cirrhosis, the severity of the hyponatremia is related to the severity of the underlying disease. As a result, hyponatremia is an independent predictor of an adverse prognosis (",
"    <a class=\"graphic graphic_figure graphicRef55554 \" href=\"UTD.htm?29/6/29805\">",
"     figure 8",
"    </a>",
"    ), with the prognosis becoming progressively worse at lower plasma sodium concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11018/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In a study of patients with cirrhosis who were candidates for liver transplantation, the hazard ratio for death was 1.05 per 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    decrease in plasma sodium at values between 140 and 125",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11018/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Hyponatremia'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=see_link&amp;anchor=H3#H3\">",
"     \"Hyponatremia in patients with heart failure\", section on 'Predictor of adverse prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=see_link&amp;anchor=H7#H7\">",
"     \"Hyponatremia in patients with cirrhosis\", section on 'Predictor of adverse prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96014936\">",
"    <span class=\"h2\">",
"     Combined regulation of plasma tonicity and effective arterial blood volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion dealt with regulation of plasma tonicity (and osmolality) and the effective arterial blood volume as isolated events. However, changes often occur in both parameters. In these settings, the hormonal response results in the excretion of urine with a composition that is similar to what has been taken in. (See",
"    <a class=\"local\" href=\"#H37261267\">",
"     'Effective arterial blood volume'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H37261099\">",
"     'Plasma tonicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A simple example is the intravenous administration of one-half isotonic saline (sodium concentration 77",
"    <span class=\"nowrap\">",
"     meq/L),",
"    </span>",
"    which will produce both volume expansion and, because it is a solution that is dilute to plasma, a reduction in the plasma sodium concentration. This will lead to the following changes in hormone secretion and urine composition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ensuing volume expansion induced by saline administration will reduce the activity of the renin-angiotensin-aldosterone system and increase the secretion of natriuretic peptides, both of which will promote the appropriate excretion of the excess sodium.",
"     </li>",
"     <li>",
"      The reduction in plasma sodium concentration and plasma tonicity induced by the infusion of a dilute fluid will suppress the release of ADH, resulting in a reduction in urine osmolality and an appropriate increase in water excretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The changes are in the opposite direction with exercise on a hot day that leads to the loss of dilute sodium-containing fluid as sweat. The net effect is a rise in the plasma sodium concentration and a fall in the extracellular volume. This will lead to the following changes in hormone secretion and urine composition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The increase in plasma sodium concentration and plasma tonicity will stimulate both ADH release and thirst; the ensuing rise in urine osmolality and subsequent water retention return the plasma sodium concentration toward normal.",
"     </li>",
"     <li>",
"      The associated hypovolemia will activate the renin-angiotensin-aldosterone system and suppress the release of natriuretic peptides, resulting in a fall in urinary sodium excretion.",
"     </li>",
"     <li>",
"      The net effect is that the urine will initially be concentrated (to prevent further water loss) and contain relatively little sodium, an appropriate response to hypertonicity and volume depletion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A third example is the ingestion of salted pretzels without intake of water. The following sequence would occur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Salt intake will raise the plasma sodium concentration, plasma osmolality, and tonicity. (See",
"      <a class=\"local\" href=\"#H37261099\">",
"       'Plasma tonicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The increase in plasma tonicity will stimulate ADH release (",
"      <a class=\"graphic graphic_figure graphicRef65195 \" href=\"UTD.htm?14/61/15325\">",
"       figure 2",
"      </a>",
"      ), reducing water excretion to prevent a further rise in the plasma sodium concentration.",
"     </li>",
"     <li>",
"      The increase in plasma tonicity will also cause osmotic water movement from the cells into the ECF. The ensuing ECF volume expansion will increase the release of natriuretic peptides and suppress the renin-angiotensin-aldosterone system, resulting in increased sodium excretion.",
"     </li>",
"     <li>",
"      The net effect is excretion of urine with a high sodium concentration and low volume, similar to what was taken in. In addition, the increase in plasma tonicity will increase thirst leading to water intake.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11437584\">",
"    <span class=\"h3\">",
"     Isotonic saline in SIADH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined regulation of water and sodium balance may produce unintentional and undesirable consequences in the treatment of hyponatremia due to the SIADH. The mainstay of therapy is fluid restriction and, in symptomatic patients, hypertonic saline. In patients who are not symptomatic, there may be a tendency to give isotonic saline. However, in most patients with SIADH, isotonic saline will",
"    <strong>",
"     not",
"    </strong>",
"    raise the plasma sodium and will often",
"    <strong>",
"     worsen",
"    </strong>",
"    the hyponatremia. This issue is discussed in detail elsewhere, but why this occurs can be illustrated by the following scenario. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Intravenous saline'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Suppose a patient with SIADH has a plasma sodium concentration of 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and a urine osmolality that is substantially higher than plasma due to the persistent effect of ADH (eg, urine sodium plus potassium concentration of 258",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and total urine osmolality of 616",
"    <span class=\"nowrap\">",
"     mosmol/kg):",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient is given 1000 mL of isotonic saline (which contains 154 meq each of sodium and chloride or 308 mosmol), the plasma sodium will initially rise because isotonic saline has a higher sodium concentration than the plasma.",
"     </li>",
"     <li>",
"      However, all 154 meq of infused sodium will be excreted (since sodium handling is intact in SIADH) but in only 600 mL of water (258",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      x 0.6 L &asymp; 154 meq).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The net effect will be retention of 400 mL of water and worsening of the hyponatremia. To raise the plasma sodium concentration with intravenous saline in patients with SIADH, the concentration of sodium plus potassium (ie, tonicity) of the infused solution must exceed the concentration of sodium plus potassium of the",
"    <strong>",
"     urine, not simply the plasma",
"    </strong>",
"    (see",
"    <a class=\"local\" href=\"#H325761326\">",
"     'Determinants of the plasma sodium concentration'",
"    </a>",
"    below). Since the urine osmolality is almost always above 300",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    in hyponatremic patients with SIADH, urine electrolyte concentrations often equal or exceed the plasma sodium concentration so that isotonic saline alone is not an effective therapy. If salt is to be given to raise the plasma sodium concentration, hypertonic saline or oral salt tablets are required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H696894934\">",
"    <span class=\"h3\">",
"     Hypertonic saline in SIADH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppose the patient in the preceding section who had hyponatremia due to SIADH and a concentrated urine is treated with hypertonic (3 percent) saline, which has a sodium concentration of 513",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Even if the urine is maximally concentrated, the sodium plus potassium concentration is not usually much higher than 250",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    . Thus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If 1000 mL of 3 percent sodium chloride is given (513 meq of sodium), the plasma sodium will initially rise because hypertonic saline has a higher sodium concentration than the plasma.",
"     </li>",
"     <li>",
"      All 513 meq of the infused sodium will be excreted (since sodium handling is intact in SIADH). If the sodium plus potassium concentration in the urine is, for example, 258",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      the infused sodium will be excreted in approximately 2 L of urine.",
"     </li>",
"     <li>",
"      The net effect is the loss of roughly 1000 mL of water, which will tend to raise the plasma sodium by about 5",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the urine osmolality is very high in SIADH, relatively large volumes of hypertonic saline may be required to achieve the desired increase in serum sodium. In such patients, concurrent use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    , which blocks the renal concentrating mechanism, with hypertonic saline [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11018/abstract/11\">",
"     11",
"    </a>",
"    ] or, alternatively, a vasopressin antagonist instead of hypertonic saline may be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Therapies to raise the serum sodium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H838162389\">",
"    <span class=\"h1\">",
"     THE STEADY STATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding section described the mechanisms by which sodium and water balance are regulated. The hormonal changes that occur allow the effective arterial blood volume and plasma tonicity to be maintained within a narrow range even in the presence of wide variations in intake from day to day. (See",
"    <a class=\"local\" href=\"#H37261267\">",
"     'Effective arterial blood volume'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H37261099\">",
"     'Plasma tonicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An important related issue is how balance (defined as intake and net losses being equal) is maintained with changes in water or sodium (or potassium) intake or excretion in patients without advanced renal failure or an edematous state such as heart failure or cirrhosis. There are two mechanisms by which this might occur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A set point which acts to maintain the plasma sodium and potassium concentrations and the extracellular fluid (ECF) volume at specific levels.",
"     </li>",
"     <li>",
"      A steady state in which intake and output are maintained at an equal level. In contrast to the set point mechanism, the plasma sodium, potassium concentration, and the ECF volume vary in the steady state to provide the signal that intake or urinary excretion (eg, with diuretic therapy) has changed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Water, sodium, and potassium balance are primarily achieved by maintenance of the",
"    <strong>",
"     steady state",
"    </strong>",
"    as illustrated by the following observations from different studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressively increasing sodium intake from 10 up to 350",
"      <span class=\"nowrap\">",
"       meq/day",
"      </span>",
"      (which is well above the 100 to 250 meq per day sodium intake on a typical American diet) is associated with an appropriate equivalent increase in sodium excretion (",
"      <a class=\"graphic graphic_figure graphicRef58458 \" href=\"UTD.htm?15/42/16045\">",
"       figure 9",
"      </a>",
"      ) that is mediated by increased release of atrial natriuretic peptide and decreased activity of the sodium-retaining renin-angiotensin-aldosterone system (",
"      <a class=\"graphic graphic_figure graphicRef53243 \" href=\"UTD.htm?0/58/941\">",
"       figure 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/48/11018/abstract/12\">",
"       12",
"      </a>",
"      ]. The signal that drives the hormonal response is a mild, and usually subclinical retention of sodium during the first few days before balance between intake and excretion is restored (",
"      <a class=\"graphic graphic_figure graphicRef58458 \" href=\"UTD.htm?15/42/16045\">",
"       figure 9",
"      </a>",
"      ). The degree of volume expansion that occurs is proportional to the magnitude of the increase in sodium intake.",
"      <br/>",
"      <br/>",
"      A similar sequence occurs when sodium reabsorption is increased in primary aldosteronism: initial sodium retention, with the ensuing extracellular volume expansion providing the signal to increase sodium excretion back to the level of sodium intake (at least in part mediated by increased natriuretic peptide secretion) (",
"      <a class=\"graphic graphic_figure graphicRef62044 \" href=\"UTD.htm?28/29/29150\">",
"       figure 10",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/48/11018/abstract/13\">",
"       13",
"      </a>",
"      ]. The net effect of this phenomenon, which is called aldosterone escape, is reattainment of the steady state with no edema. Similar considerations apply to the plasma potassium concentration. The initial urinary potassium wasting induced by hyperaldosteronism returns to the level of intake due to the direct potassium-conserving effect of hypokalemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical features of primary aldosteronism\", section on 'The steady state'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When a thiazide diuretic is given to nonedematous patients (eg, for the treatment of hypertension or nephrolithiasis associated with hypercalciuria), the initial diuresis and kaliuresis are, within a period of days, counterbalanced by sodium-retaining forces (eg, aldosterone and possibly the reduction in blood pressure) and potassium-retaining forces (eg, the direct effect of the fall in plasma potassium) that limit further sodium and potassium excretion in excess of intake. In a study evaluating the urinary responses to 100 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      per day (much higher than usual current dosing), the sodium wasting (ie, excretion greater than intake) ceased by day 4, and the potassium wasting ceased by day 10 (",
"      <a class=\"graphic graphic_figure graphicRef74940 \" href=\"UTD.htm?15/33/15901\">",
"       figure 11",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/48/11018/abstract/14\">",
"       14",
"      </a>",
"      ]. At this point, sodium and potassium intake and excretion are in balance, but the previous losses will persist at that level unless the diuretic dose or sodium or potassium intake is changed.",
"      <br/>",
"      <br/>",
"      Similarly, when an intravenous loop diuretic is given at a constant dose to stable patients, the maximum diuresis occurs after the first dose with bolus therapy and in the first few hours with an intravenous infusion (",
"      <a class=\"graphic graphic_figure graphicRef75714 \" href=\"UTD.htm?31/33/32285\">",
"       figure 12",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/48/11018/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6868?source=see_link\">",
"       \"Time course of loop and thiazide diuretic-induced electrolyte complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The urine output can exceed 10",
"      <span class=\"nowrap\">",
"       L/day",
"      </span>",
"      in normal individuals if water intake is increased to that level. This response is mediated by reduced secretion of antidiuretic hormone (ADH), which permits excretion of the excess water in a dilute urine. The signal for this response is retention of some of the excess water in the first day, resulting in a fall in the plasma sodium concentration and therefore the plasma osmolality (",
"      <a class=\"graphic graphic_figure graphicRef65195 \" href=\"UTD.htm?14/61/15325\">",
"       figure 2",
"      </a>",
"      ). A clinical setting in which increased fluid intake is recommended is for the prevention of recurrent kidney stones. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link&amp;anchor=H4#H4\">",
"       \"Prevention of recurrent calcium stones in adults\", section on 'Increase fluid intake'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OVERVIEW OF DISORDERS OF WATER AND SODIUM BALANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in plasma tonicity and the extracellular volume lead to the following four basic disorders of water and sodium balance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/48/11018/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyponatremia (too much water)",
"     </li>",
"     <li>",
"      Hypernatremia (too little water)",
"     </li>",
"     <li>",
"      Hypovolemia (too little sodium, the main extracellular solute)",
"     </li>",
"     <li>",
"      Edema (too much sodium with associated water retention)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12764206\">",
"    <span class=\"h2\">",
"     Disorders of water balance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general principles that underlie the primary disorders of water balance (hyponatremia and hypernatremia) are briefly described in the ensuing sections. The etiology and evaluation of these disorders are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link\">",
"     \"Etiology and evaluation of hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Before discussing hyponatremia and hypernatremia, it is useful to review the determinants of the plasma sodium concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H325761326\">",
"    <span class=\"h3\">",
"     Determinants of the plasma sodium concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sodium and accompanying anions (mostly chloride and bicarbonate) are the main determinants of the plasma and extracellular fluid (ECF) osmolality. In contrast, intracellular potassium and accompanying anions are the main determinant of the intracellular osmolality.",
"   </p>",
"   <p>",
"    Since water freely crosses most cells, the osmolality is the",
"    <strong>",
"     same",
"    </strong>",
"    in the extracellular and intracellular fluids. Thus, the plasma sodium concentration reflects the osmolality in both compartments even though potassium is the major intracellular cation. These relationships lead to the following formula:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(Nae &nbsp;+ &nbsp;Ke)",
"    <br/>",
"    Plasma sodium &nbsp; &asymp; &nbsp; -------------------- &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Total body water",
"   </p>",
"   <p>",
"    The subscript \"e\" refers to exchangeable sodium since approximately 30 percent of total body sodium and a smaller fraction of total body potassium are bound in areas such as bone where they are nonexchangeable and osmotically inactive.",
"   </p>",
"   <p>",
"    This relationship applies over a wide range of plasma sodium concentrations (",
"    <a class=\"graphic graphic_figure graphicRef71817 \" href=\"UTD.htm?42/31/43518\">",
"     figure 3",
"    </a>",
"    ). The derivation of this formula is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link&amp;anchor=H190652569#H190652569\">",
"     \"Etiology and evaluation of hypernatremia\", section on 'Determinants of the serum sodium concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia is almost always due to the oral or intravenous intake of water that cannot be completely excreted. Normal individuals can excrete more than 10 L of urine per day (and more than 400 mL per hour) and therefore will not develop hyponatremia unless water intake exceeds this value, which occurs most often in psychotic patients with primary polydipsia. Hyponatremia caused by massive water intake rapidly resolves as soon as water intake stops, provided that the ability to dilute the urine is intact.",
"   </p>",
"   <p>",
"    Persistent hyponatremia is associated with",
"    <strong>",
"     impaired water excretion",
"    </strong>",
"    that is most often due to an inability to suppress the release of antidiuretic hormone (ADH) or to advanced renal failure. The two major causes of persistent ADH secretion are the syndrome of inappropriate ADH secretion (SIADH) and reduced effective arterial blood volume. The latter can be due to true volume depletion (eg, diuretics, vomiting, or diarrhea) or to decreased tissue perfusion in heart failure or cirrhosis. In the last two disorders, the severity of the hyponatremia parallels the severity of the underlying disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H5#H5\">",
"     \"Causes of hyponatremia\", section on 'Hyponatremia with a low serum osmolality'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=see_link&amp;anchor=H3#H3\">",
"     \"Hyponatremia in patients with heart failure\", section on 'Predictor of adverse prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=see_link&amp;anchor=H7#H7\">",
"     \"Hyponatremia in patients with cirrhosis\", section on 'Predictor of adverse prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although water is retained in patients with hyponatremia, the degree of ECF volume expansion is not clinically important. The cell membranes are permeable to water, and approximately two-thirds of the excess fluid moves into the cells.",
"   </p>",
"   <p>",
"    Hyponatremia due to water retention is typically associated with a reduction in plasma osmolality and tonicity (see",
"    <a class=\"local\" href=\"#H37261099\">",
"     'Plasma tonicity'",
"    </a>",
"    above). This initially creates an osmotic gradient that favors water movement from the ECF into cells and the brain. Water movement into the brain can lead to cerebral edema and potentially severe neurologic symptoms, particularly if the hyponatremia is acute. In addition, overly rapid correction of severe chronic hyponatremia can lead to potentially irreversible neurologic injury. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H2#H2\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Hyponatremia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although hyponatremia is usually associated with a reduction in plasma osmolality, this is not always the case as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyponatremia can be caused by osmotic water movement out of the cells, which increases the extracellular volume and, by dilution, lowers the plasma sodium concentration. This phenomenon can occur when hyperosmolality is induced by hyperglycemia or the administration of hypertonic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      . Because plasma tonicity is increased, these patients do",
"      <strong>",
"       not",
"      </strong>",
"      experience an increase in intracellular and brain volume caused by water movement into the cells. To the contrary, hypertonicity results in water movement out of the cells and the brain. The movement of water out of the brain with hypertonic mannitol provides the rationale for its use in the treatment of cerebral edema and increased intracranial pressure. The plasma sodium rises toward its baseline value as the hyperglycemia is treated or the mannitol is excreted in the urine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link&amp;anchor=H30#H30\">",
"       \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Mannitol'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H16#H16\">",
"       \"Causes of hyponatremia\", section on 'Hyponatremia with a high or normal serum osmolality'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link&amp;anchor=H23#H23\">",
"       \"Elevated intracranial pressure in children\", section on 'Mannitol'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyponatremia may be associated with a normal or high plasma osmolality in patients with renal failure in whom the osmotic effect of urea retention counterbalances the reduction in plasma osmolality induced by the hyponatremia. However, urea readily diffuses into cells and is considered an",
"      <strong>",
"       ineffective osmole",
"      </strong>",
"      . The plasma tonicity (ie, effective plasma osmolality) is equal to the plasma osmolality minus the contribution of urea and is reduced in proportion to the reduction in plasma sodium. Thus, these patients can develop the manifestations of hyponatremia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H13#H13\">",
"       \"Causes of hyponatremia\", section on 'Advanced renal failure'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H37261099\">",
"       'Plasma tonicity'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H2#H2\">",
"       \"Manifestations of hyponatremia and hypernatremia\", section on 'Hyponatremia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evaluation and treatment of hyponatremia varies with the cause and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link\">",
"     \"Overview of the treatment of hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypernatremia is most often caused by the failure to replace water losses due to impaired thirst or lack of access to water. It can also be induced by the intake of salt in excess of water or the administration of a hypertonic salt solution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link\">",
"     \"Etiology and evaluation of hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to hyponatremia in which water moves into the cells, the increase in plasma tonicity in hypernatremia usually pulls water out of the cells, resulting in a decrease in intracellular volume.",
"   </p>",
"   <p>",
"    The clinical manifestations that may be associated with hypernatremia and the evaluation and treatment of hypernatremia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H9#H9\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Hypernatremia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link&amp;anchor=H6017462#H6017462\">",
"     \"Etiology and evaluation of hypernatremia\", section on 'Evaluation of hypernatremia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=see_link\">",
"     \"Treatment of hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12764214\">",
"    <span class=\"h2\">",
"     Disorders of sodium balance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two disorders of sodium balance are hypovolemia and edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hypovolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypovolemia refers to any condition in which the ECF volume is reduced and, when severe, can lead to hypotension or shock. Hypovolemia is usually induced by salt and water losses that are not replaced (eg, vomiting, diarrhea, diuretic therapy, bleeding, or third-space sequestration). In contrast, primary water loss, due to insensible loss by evaporation from the skin and respiratory tract or to increased urinary water loss due to diabetes insipidus, does",
"    <strong>",
"     not",
"    </strong>",
"    usually lead to hypovolemia for two reasons: the associated rise in plasma tonicity stimulates thirst, leading to replacement of most of the lost water; and water is lost disproportionately from the intracellular fluid compartment which contains approximately two-thirds of the total body water. (See",
"    <a class=\"local\" href=\"#H24579285\">",
"     'Intracellular fluid volume'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    True hypovolemia due to fluid losses should be distinguished from decreased tissue perfusion in heart failure and cirrhosis in which cardiac dysfunction and systemic vasodilation, respectively, are the major hemodynamic abnormalities. (See",
"    <a class=\"local\" href=\"#H37261267\">",
"     'Effective arterial blood volume'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1542003\">",
"    <span class=\"h4\">",
"     Concurrent changes in plasma sodium concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma sodium concentration in hypovolemic patients may be normal, low (most often due to hypovolemia-induced release of ADH, which limits urinary water excretion), or high (if water intake is impaired). The effect on the plasma sodium concentration depends upon both the composition of the fluid that is lost and fluid intake.",
"   </p>",
"   <p>",
"    In true hypovolemia due to vomiting, diarrhea, or diuretic therapy, the direct effect of fluid loss on the plasma sodium concentration depends upon the concentration of",
"    <strong>",
"     sodium plus potassium",
"    </strong>",
"    in the fluid that is lost (",
"    <a class=\"graphic graphic_figure graphicRef71817 \" href=\"UTD.htm?42/31/43518\">",
"     figure 3",
"    </a>",
"    ). The rationale for including the potassium concentration is discussed above. (See",
"    <a class=\"local\" href=\"#H325761326\">",
"     'Determinants of the plasma sodium concentration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If, as occurs in most cases of vomiting and diarrhea, the sodium plus potassium concentration in the fluid that is lost is",
"      <strong>",
"       less",
"      </strong>",
"      than the plasma sodium concentration, water is lost in excess of sodium plus potassium which will tend to",
"      <strong>",
"       increase",
"      </strong>",
"      the plasma sodium concentration. As an example, suppose that one liter of diarrheal fluid has a sodium plus potassium concentration of 75",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      This represents the electrolytes contained in 500 mL of isotonic saline (sodium concentration 154",
"      <span class=\"nowrap\">",
"       meq/L).",
"      </span>",
"      The loss of 500 mL of isotonic electrolytes will have no effect on the plasma sodium concentration. In addition, 500 mL of electrolyte free water is excreted, which will raise the plasma sodium concentration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link&amp;anchor=H190652569#H190652569\">",
"       \"Etiology and evaluation of hypernatremia\", section on 'Determinants of the serum sodium concentration'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the sodium plus potassium concentration is the",
"      <strong>",
"       same",
"      </strong>",
"      as the plasma sodium concentration (as with bleeding), there will be",
"      <strong>",
"       no change",
"      </strong>",
"      in plasma sodium concentration induced by the fluid loss.",
"     </li>",
"     <li>",
"      If the sodium plus potassium concentration is",
"      <strong>",
"       greater",
"      </strong>",
"      than the plasma sodium concentration, as can occur with thiazide diuretics, the plasma sodium concentration will",
"      <strong>",
"       fall",
"      </strong>",
"      . The high urine sodium plus potassium concentration (which exceeds the sodium concentration of the plasma) is produced because thiazide diuretics act in the distal tubule and therefore do not interfere with urinary concentrating ability, which depends upon sodium chloride reabsorption in the loop of Henle. The high ADH levels induced by the hypovolemia result in water reabsorption and high urine osmolality and electrolyte concentrations. Loop diuretics are much less likely to have this effect because they block sodium reabsorption in the thick ascending limb of the loop of Henle, which impairs the countercurrent mechanism. As a result, the urine osmolality will be closer to isosmotic despite high ADH levels, and the sodium plus potassium concentration will be less than the plasma sodium concentration since urea also contributes to the urine osmolality. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/31/502?source=see_link&amp;anchor=H2#H2\">",
"       \"Diuretic-induced hyponatremia\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The changes in plasma sodium concentration directly induced by fluid loss do",
"    <strong>",
"     not",
"    </strong>",
"    necessarily represent the final outcome. Hypovolemia stimulates nonosmotic release of ADH, which will promote retention of ingested water or infused electrolyte-free water, which will lower the plasma sodium concentration, independent of the composition of the fluid lost. (See",
"    <a class=\"local\" href=\"#H165025668\">",
"     'Later role of ADH'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H7#H7\">",
"     \"Causes of hyponatremia\", section on 'True volume depletion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Edema (including ascites) is a manifestation of sodium excess and an expanded ECF volume. Movement of fluid out of the vascular space into the interstitium is most often mediated by an increase in capillary hydraulic pressure. The pathophysiology of edema formation is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathophysiology and etiology of edema in adults\", section on 'Edema formation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tissue perfusion is variable in these disorders, depending upon the cause of edema:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When due to renal failure or glomerulonephritis, tissue perfusion may be increased if cardiac function is intact.",
"     </li>",
"     <li>",
"      When due to heart failure or cirrhosis, tissue perfusion is often reduced due to decreased cardiac function and vasodilation, respectively. (See",
"      <a class=\"local\" href=\"#H37261267\">",
"       'Effective arterial blood volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When due to the nephrotic syndrome, tissue perfusion may be reduced due to hypoalbuminemia or increased due to primary renal sodium retention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36008?source=see_link&amp;anchor=H1#H1\">",
"       \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\", section on 'Underfilling versus renal sodium retention'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H451539334\">",
"    <span class=\"h4\">",
"     Effect on plasma sodium concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sodium retention in edematous patients is",
"    <strong>",
"     not",
"    </strong>",
"    associated with hypernatremia since a proportionate amount of water is retained. However, hyponatremia can occur if there is a concurrent reduction in the ability to excrete water. As an example, hyponatremia is common in patients with heart failure and cirrhosis because the reduction in tissue perfusion increases the secretion of ADH, thereby limiting the excretion of ingested water. In these disorders, the severity of hyponatremia is directly related to the severity of the underlying disease and is therefore a predictor of an adverse prognosis. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Hyponatremia'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=see_link&amp;anchor=H3#H3\">",
"     \"Hyponatremia in patients with heart failure\", section on 'Predictor of adverse prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=see_link&amp;anchor=H7#H7\">",
"     \"Hyponatremia in patients with cirrhosis\", section on 'Predictor of adverse prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6574982\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following terms are commonly used when discussing disorders of water and sodium balance (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above): &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Total body water (TBW) &ndash; A percentage of lean body weight that varies with age; approximate normal values are 80 percent in premature infants, 70 to 75 percent in term infants, 65 to 70 percent in toddlers, and 60 percent after puberty (",
"      <a class=\"graphic graphic_figure graphicRef56512 \" href=\"UTD.htm?32/46/33518\">",
"       figure 1",
"      </a>",
"      ). TBW as a percentage of total body weight is lower in young adult females than in young adult males (50 versus 60 percent) and becomes progressively lower with increasing obesity or with loss of muscle mass. The TBW has two main compartments: the extracellular fluid (ECF) and the intracellular fluid, which are separated by the cell membrane. (See",
"      <a class=\"local\" href=\"#H37261016\">",
"       'Total body water'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extracellular fluid (ECF) volume &ndash; The ECF component is greater in infants and young children compared with older patients (",
"      <a class=\"graphic graphic_figure graphicRef56512 \" href=\"UTD.htm?32/46/33518\">",
"       figure 1",
"      </a>",
"      ). In normal adults, the ECF constitutes approximately 33 to 40 percent of the TBW in normal adults and is determined by the absolute amounts of sodium and water that are present in the ECF. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Extracellular fluid volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effective arterial blood volume &ndash; The hormonal changes that regulate the ECF volume are mediated by sensors that respond to changes in pressure and tissue perfusion, not volume. In most settings, pressure and volume change in parallel with changes in sodium intake or with sodium losses. However, the ECF volume and tissue perfusion do not always change in the same direction. Two common examples are heart failure with edema and cirrhosis with ascites. In both disorders, the ECF volume is increased, but tissue perfusion is reduced. Reduced effective arterial blood volume is a term that has been used to describe the discrepancy between hypoperfusion and the increase in extracellular volume in heart failure and cirrhosis. (See",
"      <a class=\"local\" href=\"#H37261267\">",
"       'Effective arterial blood volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intracellular fluid volume &ndash; In normal adults, the intracellular fluid volume constitutes approximately 60 to 67 percent of TBW. Potassium salts are the main intracellular solutes, and the intracellular fluid volume is larger than the ECF volume because there are more potassium salts in the cells than sodium salts in the ECF. Changes in the intracellular fluid volume primarily occur when there are changes in plasma tonicity, resulting in water movement into or out of the cells. (See",
"      <a class=\"local\" href=\"#H24579285\">",
"       'Intracellular fluid volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plasma osmolality (Posm) &ndash; The Posm is determined by the ratio of plasma solute particles and plasma water. Most of the plasma solutes are dissociated sodium salts with lesser contributions from other ions (eg, potassium, calcium), glucose, and urea. The normal Posm is 275 to 290",
"      <span class=\"nowrap\">",
"       mosmol/kg.",
"      </span>",
"      The plasma osmolality can be estimated (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?27/45/28370?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) or measured. The plasma and ECF osmolality are the same as the intracellular osmolality since most cell membranes are freely permeable to water, which flows from areas of lower osmolality to those with higher osmolality. (See",
"      <a class=\"local\" href=\"#H37261092\">",
"       'Plasma osmolality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plasma tonicity &ndash; Plasma tonicity is the effective plasma osmolality, which is sensed by osmoreceptors and determines the transcellular distribution of water. Water can freely cross almost all cell membranes and moves from an area of lower tonicity (higher water content) to an area of higher tonicity (lower water content). The main difference between plasma tonicity and plasma osmolality is that plasma tonicity reflects the concentration of solutes that do not easily cross cell membranes (mostly sodium salts) and therefore affect the distribution of water between the cells and the ECF. The plasma osmolality includes the osmotic contribution of urea, which is considered an \"ineffective\" osmole since it can equilibrate across the cell membrane and therefore has little effect on water movement across the cell membrane. (See",
"      <a class=\"local\" href=\"#H37261099\">",
"       'Plasma tonicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dehydration versus hypovolemia &ndash; Dehydration is defined as a reduction in TBW below the normal level without a proportional reduction in sodium and potassium, resulting in a rise in the plasma sodium concentration (hypernatremia). Because water equilibrates across the cell membrane, about two-thirds of water losses come from the cells, and only one-third come from the ECF, thereby preserving effective arterial blood volume. Thus, signs of hypovolemia are not present in patients with dehydration unless there is a marked degree of free water loss. (See",
"      <a class=\"local\" href=\"#H165025474\">",
"       'Dehydration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The kidney regulates water and sodium balance independently since water can be taken in without salt and salt can be taken in without water. Regulation of plasma tonicity and of the effective arterial blood volume involve different hormones, although there are some areas of overlap. (See",
"      <a class=\"local\" href=\"#H96014928\">",
"       'Regulation of water and sodium balance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osmoregulation (regulation of the plasma tonicity) is achieved by alterations in water balance. Suppression of ADH release is the primary protective mechanism against water retention and the development of hyponatremia, while thirst is the primary protective mechanism against water loss and the development of hypernatremia. (See",
"      <a class=\"local\" href=\"#H96014898\">",
"       'Regulation of plasma tonicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Changes in effective arterial blood volume are sensed by three major pressure receptors which activate specific systems that regulate both systemic vascular resistance and sodium excretion (",
"      <a class=\"graphic graphic_table graphicRef51153 \" href=\"UTD.htm?22/41/23195\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H96014906\">",
"       'Regulation of effective arterial blood volume'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Juxtaglomerular cells, which sense the perfusion pressure in the kidney, are an important determinant of the activity of the renin-angiotensin-aldosterone system, which increases with renal hypoperfusion (",
"      <a class=\"graphic graphic_figure graphicRef69949 \" href=\"UTD.htm?31/9/31889\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef65116 \" href=\"UTD.htm?14/19/14654\">",
"       figure 5",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      Receptors in the carotid sinus and aorta regulate the activity of the sympathetic nervous system. Increased sympathetic activity also increases renin release (",
"      <a class=\"graphic graphic_figure graphicRef65116 \" href=\"UTD.htm?14/19/14654\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cardiac receptors regulate the release of atrial natriuretic peptide (mostly from the atria) and brain natriuretic peptide (mostly from the ventricles).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In response to volume expansion due, for example, to a high salt intake, natriuretic peptide secretion is increased while the renin-angiotensin-aldosterone system is suppressed (",
"      <a class=\"graphic graphic_figure graphicRef53243 \" href=\"UTD.htm?0/58/941\">",
"       figure 6",
"      </a>",
"      ); these changes promote urinary sodium excretion and a reduction in the ECF volume. In contrast, a reduction in effective arterial blood volume due, for example, to volume contraction will activate the renin-angiotensin-aldosterone and sympathetic nervous systems. These hormonal changes result in both sodium retention and vasoconstriction, thereby maintaining the ECF and systemic blood pressure. (See",
"      <a class=\"local\" href=\"#H96014906\">",
"       'Regulation of effective arterial blood volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regulation of plasma tonicity and the effective arterial blood volume occur simultaneously; the hormonal response normally results in the excretion of urine with a composition that is similar to what has been taken in. (See",
"      <a class=\"local\" href=\"#H96014936\">",
"       'Combined regulation of plasma tonicity and effective arterial blood volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hormonal changes that occur allow the effective arterial blood volume and plasma tonicity to be maintained within a narrow range even in the presence of wide variations in intake from day to day. (See",
"      <a class=\"local\" href=\"#H838162389\">",
"       'The steady state'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormalities in plasma tonicity and the extracellular volume lead to the following four basic disorders of water and sodium balance (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Overview of disorders of water and sodium balance'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hyponatremia (too much water or overhydration). (See",
"      <a class=\"local\" href=\"#H12764206\">",
"       'Disorders of water balance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypernatremia (too little water or dehydration). (See",
"      <a class=\"local\" href=\"#H12764206\">",
"       'Disorders of water balance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypovolemia (too little sodium, the main extracellular solute or volume contraction). (See",
"      <a class=\"local\" href=\"#H12764214\">",
"       'Disorders of sodium balance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypervolemia (too much sodium, the main extracellular solute,&nbsp;with expansion of the effective arterial blood volume and hypertension). (See",
"      <a class=\"local\" href=\"#H12764214\">",
"       'Disorders of sodium balance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Edema or hypervolemia (too much sodium with associated water retention in interstitial spaces). (See",
"      <a class=\"local\" href=\"#H12764214\">",
"       'Disorders of sodium balance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11018/abstract/1\">",
"      FRIIS-HANSEN B. Body water compartments in children: changes during growth and related changes in body composition. Pediatrics 1961; 28:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11018/abstract/2\">",
"      EDELMAN IS, LEIBMAN J. Anatomy of body water and electrolytes. Am J Med 1959; 27:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11018/abstract/3\">",
"      Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab 2003; 17:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11018/abstract/4\">",
"      Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev 2010; 90:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11018/abstract/5\">",
"      Lahiri S, Nishino T, Mokashi A, Mulligan E. Relative responses of aortic body and carotid body chemoreceptors to hypotension. J Appl Physiol 1980; 48:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11018/abstract/6\">",
"      Ghosh N, Haddad H. Atrial natriuretic peptides in heart failure: pathophysiological significance, diagnostic and prognostic value. Can J Physiol Pharmacol 2011; 89:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11018/abstract/7\">",
"      Johnston CI, Hodsman PG, Kohzuki M, et al. Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system. Endogenous antagonists. Am J Med 1989; 87:24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11018/abstract/8\">",
"      Dunn FL, Brennan TJ, Nelson AE, Robertson GL. The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest 1973; 52:3212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11018/abstract/9\">",
"      Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11018/abstract/10\">",
"      Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986; 73:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11018/abstract/11\">",
"      Hantman D, Rossier B, Zohlman R, Schrier R. Rapid correction of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. An alternative treatment to hypertonic saline. Ann Intern Med 1973; 78:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11018/abstract/12\">",
"      Sagnella GA, Markandu ND, Buckley MG, et al. Hormonal responses to gradual changes in dietary sodium intake in humans. Am J Physiol 1989; 256:R1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11018/abstract/13\">",
"      Hall JE, Granger JP, Smith MJ Jr, Premen AJ. Role of renal hemodynamics and arterial pressure in aldosterone \"escape\". Hypertension 1984; 6:I183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11018/abstract/14\">",
"      Maronde RF, Milgrom M, Vlachakis ND, Chan L. Response of thiazide-induced hypokalemia to amiloride. JAMA 1983; 249:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11018/abstract/15\">",
"      Rudy DW, Voelker JR, Greene PK, et al. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med 1991; 115:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/48/11018/abstract/16\">",
"      Mange K, Matsuura D, Cizman B, et al. Language guiding therapy: the case of dehydration versus volume depletion. Ann Intern Med 1997; 127:848.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2307 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-1.234.2.38-C3DAD56939-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_48_11018=[""].join("\n");
var outline_f10_48_11018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6574982\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37261016\">",
"      Total body water",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Extracellular fluid volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H37261267\">",
"      Effective arterial blood volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24579285\">",
"      - Intracellular fluid volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37261092\">",
"      Plasma osmolality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37261099\">",
"      Plasma tonicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H165025474\">",
"      Dehydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H96014928\">",
"      REGULATION OF WATER AND SODIUM BALANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H96014898\">",
"      Regulation of plasma tonicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H96014906\">",
"      Regulation of effective arterial blood volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H165025668\">",
"      - Later role of ADH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H96014936\">",
"      Combined regulation of plasma tonicity and effective arterial blood volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11437584\">",
"      - Isotonic saline in SIADH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H696894934\">",
"      - Hypertonic saline in SIADH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H838162389\">",
"      THE STEADY STATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OVERVIEW OF DISORDERS OF WATER AND SODIUM BALANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12764206\">",
"      Disorders of water balance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H325761326\">",
"      - Determinants of the plasma sodium concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12764214\">",
"      Disorders of sodium balance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1542003\">",
"      Concurrent changes in plasma sodium concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H451539334\">",
"      Effect on plasma sodium concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6574982\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2307\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2307|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/46/33518\" title=\"figure 1\">",
"      Total body water",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/61/15325\" title=\"figure 2\">",
"      Osmoregulation of ADH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/31/43518\" title=\"figure 3\">",
"      Determinants of plasma sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/9/31889\" title=\"figure 4\">",
"      Macula densa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/19/14654\" title=\"figure 5\">",
"      Renin release",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/58/941\" title=\"figure 6\">",
"      Hormonal response to Na load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/33/2589\" title=\"figure 7\">",
"      Volume regulation of ADH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/6/29805\" title=\"figure 8\">",
"      Hyponatremia in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/42/16045\" title=\"figure 9\">",
"      Relationship between sodium intake and excretion in steady state",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/29/29150\" title=\"figure 10\">",
"      Resumption of the steady state in primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/33/15901\" title=\"figure 11\">",
"      Time course of diuretic action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/33/32285\" title=\"figure 12\">",
"      First dose diuretic response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2307|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/41/23195\" title=\"table 1\">",
"      Osmoregulation v volume reg",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?27/45/28370?source=related_link\" title=\"calculator 1\">",
"      Calculator: Serum osmolal gap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?20/19/20786?source=related_link\" title=\"calculator 2\">",
"      Calculator: Serum osmolal gap (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=related_link\">",
"      Clinical manifestations and diagnosis of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=related_link\">",
"      Dialysis disequilibrium syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/31/502?source=related_link\">",
"      Diuretic-induced hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=related_link\">",
"      Etiology and evaluation of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17608?source=related_link\">",
"      Hyponatremia in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=related_link\">",
"      Hyponatremia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=related_link\">",
"      Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=related_link\">",
"      Pathogenesis of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=related_link\">",
"      Pathophysiology and etiology of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36008?source=related_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6868?source=related_link\">",
"      Time course of loop and thiazide diuretic-induced electrolyte complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=related_link\">",
"      Treatment of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_48_11019="Airway stent complications";
var content_f10_48_11019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Airway stent-related complications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Displacement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mucus impaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granuloma formation at stent ends",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obstruction from tumor or granuloma (uncovered stents)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Halitosis and chronic infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perforation of airway wall",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoptysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cough",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Airway fire during laser resection",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bolliger, CT, Mathur, PN, Beamis, JF, et al. Eur Respir J 2002; 19:365. Copyright &copy; 2002 European Respiratory Society Journals Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_48_11019=[""].join("\n");
var outline_f10_48_11019=null;
var title_f10_48_11020="Criteria for NTM diagnosis";
var content_f10_48_11020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical and microbiologic criteria for diagnosing nontuberculous mycobacterial (NTM) lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical (both required)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a high-resolution computed tomography scan that shows multifocal bronchiectasis with multiple small nodules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Appropriate exclusion of other diagnoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Microbiologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Positive culture results from at least two separate expectorated sputum samples. If the results from the initial sputum samples are nondiagnostic, consider repeat sputum AFB smears and cultures.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Positive culture result from at least one bronchial wash or lavage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Transbronchial or other lung biopsy with mycobacterial histopathologic features (granulomatous inflammation or AFB) and positive culture for NTM or biopsy showing mycobacterial histopathologic features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that are culture positive for NTM",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_single\">",
"        Additional considerations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Expert consultation should be obtained when NTM are recovered that are either infrequently encountered or that usually represent environmental contamination",
"         </li>",
"         <li>",
"          Patients who are suspected of having NTM lung disease but do not meet the diagnostic criteria should be followed until the diagnosis is firmly established or excluded",
"         </li>",
"         <li>",
"          Making the diagnosis of NTM lung disease does not, per se, necessitate the institution of therapy, which is a decision based on potential risks and benefits of therapy for individual patients",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Griffith DE, Aksamit T, Brown-Elliott BA, et al. An Official ATS/IDSA Statement: Diagnosis, treatment and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367. Copyright &copy; 2007 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_48_11020=[""].join("\n");
var outline_f10_48_11020=null;
var title_f10_48_11021="Prophylactic medication CVS";
var content_f10_48_11021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prophylactic or preventive medications* in CVS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Children 2 to 5 years old",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Antihistamines: cyproheptadine (first choice) and pizotifen (available in UK, Canada)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyproheptadine 0.25-0.5 mg/kg/day orally divided twice daily or three times daily (maximum 12 mg per 24 hours). (Available in 2 mg/5 mL liquid).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Side effects: increased appetite, weight gain, sedation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alternatives: pizotifen (available in UK, Canada)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Beta-blockers: propranolol (second choice)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Propranolol 0.25-1 mg/kg/day orally divided twice daily or three times daily, most often 10 mg twice daily or three times daily. Initiate at 0.25 mg/kg/day and increase every 1-4 weeks in increments of 0.25 mg/kg/day as needed and tolerated. (&lt;35 kg maximum 60 mg per 24 hours. &ge;35 kg maximum 120 mg per 24 hours). (Available in liquid).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Monitor: resting heart rate maintain &ge;60 bpm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Side effects: lethargy, reduced exercise intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Contraindications: asthma, diabetes, heart disease, depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discontinuation: tapered for 1-2 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Children older than 5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Tricyclic antidepressants: amitriptyline (first choice)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amitriptyline begin at 0.25-0.5 mg/kg/day orally at bedtime, increase every 1-4 weeks as needed and tolerated by 5-10 mg, until 1-1.5 mg/kg/day (maximum 75 mg per 24 hours). (For dose &gt;1 mg/kg/day, divide twice daily).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Monitor: &radic;EKG QT",
"        <sub>",
"         c",
"        </sub>",
"        interval before starting and 10 days after peak dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Side effects: constipation, sedation, arrhythmia, behavioral changes (especially in young children)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alternatives: nortriptyline",
"        <sup>",
"         &bull;",
"        </sup>",
"        (available in 10 mg/5 mL liquid)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Beta-blockers: propranolol (second choice) - see above",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Anticonvulsants: phenobarbital",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phenobarbital 2 mg/kg/day orally administered at bedtime (maximum 40 mg per 24 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Side effects: sedation, cognitive impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alternatives: topiramate, valproic acid, gabapentin, levetiracetam - consult Pediatric neurologist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Supplements",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        L-carnitine 50-100 mg/kg/day orally divided twice daily or three times daily (maximum 1 g three times daily)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coenzyme Q",
"        <sub>",
"         10",
"        </sub>",
"        10 mg/kg/day orally divided twice daily or three times daily (maximum 100 mg three times daily)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Side effects: diarrhea, fishy body odor (for L-carnitine)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All medication recommendations are made for off-label use.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Limited or no published experience regarding efficacy.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47:379. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_48_11021=[""].join("\n");
var outline_f10_48_11021=null;
var title_f10_48_11022="Serum markers acute HBV HDV";
var content_f10_48_11022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Serum markers of acute, self-limiting HBV/HDV coinfection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 392px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the typical serologic response to acute HBV/HDV infection. Patients should be positive for HBsAg and have high titer IgM anti-HBc; serum HDAg and/or HDV RNA are usually positive at presentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_48_11022=[""].join("\n");
var outline_f10_48_11022=null;
var title_f10_48_11023="Contents: Pediatric signs and symptoms";
var content_f10_48_11023=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric signs and symptoms",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric signs and symptoms",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acute and emergent",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/34/31272\">",
"           Apparent life-threatening event in infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/36/16970\">",
"           Approach to acute vision loss in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/38/27241\">",
"           Approach to chest pain in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/53/17241\">",
"           Approach to hypertensive emergencies and urgencies in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/4/42057\">",
"           Approach to the child with a limp",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/45/32472\">",
"           Approach to the child with acute ataxia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/8/35977\">",
"           Approach to the child with headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/60/22474\">",
"           Approach to the child with occult toxic exposure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/34/22056\">",
"           Approach to the child with palpitations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/38/9832\">",
"           Approach to the child with tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/60/24521\">",
"           Approach to the infant or child with nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/39/17018\">",
"           Approach to the septic-appearing infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/0/1033\">",
"           Approach to upper gastrointestinal bleeding in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/20/11593\">",
"           Causes of acute abdominal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/12/39113\">",
"           Causes of acute respiratory compromise in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/39/32376\">",
"           Causes of scrotal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/10/36007\">",
"           Causes of syncope in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/12/7367\">",
"           Classification of trauma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/52/29513\">",
"           Diagnostic approach to lower gastrointestinal bleeding in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/35/4666\">",
"           Emergency department evaluation of acute onset psychosis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/61/7130\">",
"           Emergent evaluation of acute respiratory compromise in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/61/10201\">",
"           Emergent evaluation of acute upper airway obstruction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/52/14153\">",
"           Emergent evaluation of headache in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/10/11432\">",
"           Emergent evaluation of syncope in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/61/22490\">",
"           Emergent evaluation of the child with acute abdominal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/16/27912\">",
"           Epidemiology and etiology of epistaxis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/41/31385\">",
"           Etiology and evaluation of cyanosis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/54/24425\">",
"           Etiology and evaluation of the child with muscle weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/39/40569\">",
"           Evaluation of dysphagia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/47/13050\">",
"           Evaluation of earache in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/42/18086\">",
"           Evaluation of epistaxis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/42/22185\">",
"           Evaluation of inguinal swelling in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/25/18842\">",
"           Evaluation of neck stiffness in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/13/26841\">",
"           Evaluation of purpura in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/38/2663\">",
"           Evaluation of scrotal pain or swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/40/12936\">",
"           Evaluation of the immobile arm in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/10/15529\">",
"           Evaluation of vaginal bleeding in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/39/30329\">",
"           Evaluation of weight loss in infants over six months of age, children, and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/33/23065\">",
"           Management of hypertensive emergencies and urgencies in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/62/33768\">",
"           Overview of blunt abdominal trauma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/32/40457\">",
"           Traumatic causes of acute shoulder pain and injury in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ambulatory",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/26/8616\">",
"           Acquired torticollis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/28/41417\">",
"           Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/34/12840\">",
"           Approach to the child with an enlarged spleen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/54/43880\">",
"           Approach to the child with anemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/22/33128\">",
"           Approach to the child with peripheral lymphadenopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/13/34004\">",
"           Approach to the infant with hypotonia and weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/36/34376\">",
"           Approach to the pediatric patient with vision change",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/45/30424\">",
"           Approach to wheezing in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/47/43766\">",
"           Causes of painless scrotal swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/1/30744\">",
"           Causes of peripheral lymphadenopathy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/63/25591\">",
"           Causes of thrombocytopenia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/27/10680\">",
"           Clinical features and etiology of colic",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/46/24295\">",
"           Clinical manifestations and evaluation of thrombocytopenia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/23/25975\">",
"           Definition and evaluation of abnormal uterine bleeding in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/57/11160\">",
"           Differential diagnosis and approach to the adolescent with abnormal uterine bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/52/15177\">",
"           Evaluation and management of colic",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/7/7288\">",
"           Evaluation and management of edema in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/26/28074\">",
"           Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/43/697\">",
"           Evaluation of acute pelvic pain in the adolescent female",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/13/13529\">",
"           Evaluation of diarrhea in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/24/29064\">",
"           Evaluation of dizziness in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/29/43479\">",
"           Evaluation of dysuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/55/30584\">",
"           Evaluation of microscopic hematuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/37/14937\">",
"           Evaluation of oligomenorrhea in adolescence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/9/24728\">",
"           Evaluation of otorrhea (ear discharge) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/27/12729\">",
"           Evaluation of pallor in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/41/26262\">",
"           Evaluation of proteinuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/31/39415\">",
"           Evaluation of sore throat in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/17/1306\">",
"           Evaluation of the child and adolescent with chronic abdominal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/39/2679\">",
"           Evaluation of the child with back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/0/4102\">",
"           Evaluation of the child with hoarseness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/46/14057\">",
"           Evaluation of the child with joint pain or swelling",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/9/23706\">",
"           Overview of the causes of limp in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/29/26072\">",
"           Vulvovaginal complaints in the prepubertal child",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-AD58C24854-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f10_48_11023=[""].join("\n");
var outline_f10_48_11023=null;
